

15. Schouten LJ, Goldbohm RA, van den Brandt PA. Anthropometry, physical activity, and endometrial cancer risk: results from the Netherlands Cohort Study. *J Natl Cancer Inst* 2004;96:1635–8.
16. Terry P, Baron JA, Weiderpass E, Yuen J, Lichtenstein P, Nyren O. Lifestyle and endometrial cancer risk: a cohort study from the Swedish Twin Registry. *Int J Cancer* 1999;82:38–42.
17. Levi F, La Vecchia C, Negri E, Franceschi S. Selected physical activities and the risk of endometrial cancer. *Br J Cancer* 1993;67:846–51.
18. Sturgeon SR, Brinton LA, Berman ML, Mortel R, Twiggs LB, Barrett RJ, Wilbanks GD. Past and present physical activity and endometrial cancer risk. *Br J Cancer* 1993;68:584–9.
19. Friberg E, Mantzoros CS, Wolk A. Physical activity and risk of endometrial cancer: a population-based prospective cohort study. *Cancer Epidemiol Biomarkers Prev* 2006;15:2136–40.
20. Colbert LH, Lacey JV Jr, Schairer C, Albert P, Schatzkin A, Albanes D. Physical activity and risk of endometrial cancer in a prospective cohort study (United States). *Cancer Causes Control* 2003;14:559–67.
21. Furberg AS, Thune I. Metabolic abnormalities (hypertension, hyperglycemia and overweight), lifestyle (high energy intake and physical inactivity) and endometrial cancer risk in a Norwegian cohort. *Int J Cancer* 2003;104:669–76.
22. Littman AJ, Voigt LF, Beresford SA, Weiss NS. Recreational physical activity and endometrial cancer risk. *Am J Epidemiol* 2001;154:924–33.
23. Shu XO, Hatch MC, Zheng W, Gao YT, Brinton LA. Physical activity and risk of endometrial cancer. *Epidemiology* 1993;4:342–9.
24. Calle EE, Rodriguez C, Jacobs EJ, Almon ML, Chao A, McCullough ML, Feigelson HS, Thun MJ. The American Cancer Society Cancer Prevention Study. II. Nutrition cohort-rational, study design, and baseline characteristics. *Cancer* 2002;94:500–11.
25. Bergmann M, Calle E, Mervis C, Miracle-McMahill H, Thun M, Heath C. Validity of self-reported cancers in a prospective cohort study in comparison to data from state cancer registries. *Am J Epidemiol* 1998;147:556–62.
26. Calle EE, Terrell D. Utility of the National Death Index for ascertainment of mortality among cancer prevention study II participants. *Am J Epidemiol* 1993;137:235–41.
27. Ainsworth BE, Haskell WL, Leon AS, Jacobs DR Jr, Montoye HJ, Sallis JF, Paffenbarger RS Jr. Compendium of physical activities: classification of energy costs of human physical activities. *Med Sci Sports Exerc* 1993;25:71–80.
28. Calle EE, Teras LR, Thun MJ. Adiposity as compared with physical activity in predicting mortality among women (letter). *N Engl J Med* 2005;352:1381–2.
29. Cox D. Regression models and life tables. *J R Stat Soc* 1972;34:187–220.
30. Kleinbaum G, Kupper L, Morgenstern H. *Epidemiologic research: principles and quantitative methods*. New York: Van Nostrand Reinhold, 1982.
31. Key TJ, Pike MC. The dose-effect relationship between ‘unopposed’ oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. *Br J Cancer* 1988;57:205–12.
32. Kramer MM, Wells CL. Does physical activity reduce risk of estrogen-dependent cancer in women? *Med Sci Sports Exerc* 1996;28:322–34.
33. Freidenreich CM. Physical activity and cancer: lessons learned from nutritional epidemiology. *Nutr Rev* 2001;59:349–57.
34. Shephard RJ. Physical activity and cancer. *Int J Sports Med* 1990;11:413–20.
35. Cauley JA, Gutai JP, Kuller LH, LeDonne D, Powell JG. The epidemiology of serum sex hormones in postmenopausal women. *Am J Epidemiol* 1989;129:1120–31.
36. Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, Clore JN, Blackard WG. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. *J Clin Endocrinol Metab* 1991;72:83–9.
37. IARC. *IARC handbooks on cancer prevention: weight control and physical activity*, vol. 6. Lyon: IARC Press, 2002.
38. Wolf AM, Hunter DJ, Colditz GA, Manson JE, Stampfer MJ, Corsano KA, Rosner B, Kriska A. Reproducibility and validity of a self-administered physical activity questionnaire. *Int J Epidemiol* 1994;23:991–9.
39. Chao A, Connell CJ, Jacobs EJ, McCullough ML, Patel AV, Calle EE, Cokkinides VE, Thun MJ. Amount, type, and timing of recreational physical activity in relation to colon and rectal cancer in older adults: the Cancer Prevention Study II Nutrition Cohort. *Cancer Epidemiol Biomarkers Prev* 2004;13:2187–95.
40. Patel AV, Calle EE, Bernstein L, Wu AH, Thun MJ. Recreational physical activity and risk of postmenopausal breast cancer in a large cohort of US women. *Cancer Causes Control* 2003;14:519–29.

| 論文名 | The role of body weight in the relationship between physical activity and endometrial cancer: results from a large cohort of US women | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|--|---|-------------|--------------------------|--------------------------|--------------------------|-------|--------|--|-------|---------|--------------------------|--------------------------|--------------------------|--|--|--|--|--|--|------|----|--------|------------------|------------------|------------------|-------|-----|---------|-------------|-------------|-------------|---------|-----|---------|------------------|------------------|------------------|------------|----|--------|------------------|------------------|------------------|-------|----|--------|------------------|------------------|------------------|--|--|--|--|-----------------|----------------|--|--|--|--|--|--|------|----|-------|------------------|------------------|------------------|--------|-----|--------|-------------|-------------|-------------|------------|-----|--------|------------------|------------------|------------------|------------|-----|--------|------------------|------------------|------------------|-------|-----|--------|------------------|------------------|------------------|--|--|--|--|-----------------|----------------|--|--|--|--|--|--|----|-----|---------|-------------|-------------|-------------|-----|-----|---------|------------------|------------------|------------------|----|----|--------|------------------|------------------|------------------|--|--|--|--|----------------|----------------|-------------------------------|--|--|--|--|--|-------------|-----|---------|-------------|-------------|-------------|----------|-----|---------|------------------|------------------|------------------|-------|----|--------|------------------|------------------|------------------|--|--|--|--|-----------------|----------------|--|--|--|--|--|--|------|----|--------|------------------|------------------|------------------|-------|-----|--------|-------------|-------------|-------------|---------|-----|---------|------------------|------------------|------------------|------------|----|--------|------------------|------------------|------------------|----------|----|--------|------------------|------------------|------------------|-----|----|--------|------------------|------------------|------------------|--|--|--|--|----------------|----------------|-----------------------------------|--|--|--|--|--|-----------------------|-----|--------|-------------|-------------|-------------|---------------------|----|--------|------------------|------------------|------------------|---------------------|-----|---------|------------------|------------------|------------------|-------------------|----|--------|------------------|------------------|------------------|
| 著者 | Patel AV, Feigelson HS, Talbot JT, McCullough ML, Rodriguez C, Patel RC, Thun MJ, Calle EE | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 雑誌名 | Int J Cancer | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 巻・号・頁 | 123 1877-1882 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 発行年 | 2008 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| PubMedリンク | http://www.ncbi.nlm.nih.gov/pubmed/18651569 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 対象の内訳 | | ヒト | 動物 | 地域 | 欧米 | 研究の種類 | 縦断研究 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 対象 | 一般健常者 | 空白 | | () | | コホート研究 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 性別 | 女性 | () | | () | | () | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 年齢 | 62.8(±6.0)歳 | | | () | | 前向き研究 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 対象数 | 10000以上 | | | () | | () | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 調査の方法 | 質問紙 | () | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| アウトカム | 予防 | なし | なし | ガン予防 | なし | () | () | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 維持・改善 | なし | なし | なし | なし | () | () | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 図表 | <p>TABLE II - HAZARD RATE RATIOS (RR) AND 95% CONFIDENCE INTERVALS (CI) FOR MEASURES OF PHYSICAL ACTIVITY AT VARIOUS POINTS IN TIME AND ENDOMETRIAL CANCER, CPS-II NUTRITION COHORT, 1992-2001</p> <table border="1"> <thead> <tr> <th></th> <th>Cases</th> <th>p-years</th> <th>RR¹ (95% CI)</th> <th>RR² (95% CI)</th> <th>RR³ (95% CI)</th> </tr> </thead> <tbody> <tr> <td colspan="6">Baseline recreational activity MET-hr/week</td> </tr> <tr> <td>None</td> <td>43</td> <td>34,622</td> <td>0.92 (0.66-1.28)</td> <td>0.93 (0.67-1.30)</td> <td>0.84 (0.60-1.17)</td> </tr> <tr> <td>0<-<7</td> <td>170</td> <td>124,302</td> <td>1.00 (ref.)</td> <td>1.00 (ref.)</td> <td>1.00 (ref.)</td> </tr> <tr> <td>7-<17.5</td> <td>157</td> <td>133,553</td> <td>0.86 (0.69-1.07)</td> <td>0.86 (0.70-1.07)</td> <td>0.92 (0.74-1.14)</td> </tr> <tr> <td>17.5-<31.5</td> <td>72</td> <td>75,456</td> <td>0.70 (0.53-0.92)</td> <td>0.70 (0.53-0.93)</td> <td>0.80 (0.60-1.05)</td> </tr> <tr> <td>31.5+</td> <td>24</td> <td>27,264</td> <td>0.65 (0.42-1.00)</td> <td>0.67 (0.44-1.03)</td> <td>0.79 (0.52-1.22)</td> </tr> <tr> <td></td> <td></td> <td></td> <td></td> <td>p-trend = 0.007</td> <td>p-trend = 0.18</td> </tr> <tr> <td colspan="6">Baseline nonrecreational activity MET-hr/week⁴</td> </tr> <tr> <td>None</td> <td>11</td> <td>5,473</td> <td>1.45 (0.78-2.69)</td> <td>1.44 (0.78-2.66)</td> <td>1.31 (0.71-2.44)</td> </tr> <tr> <td>>0-5.0</td> <td>132</td> <td>96,620</td> <td>1.00 (ref.)</td> <td>1.00 (ref.)</td> <td>1.00 (ref.)</td> </tr> <tr> <td>>5.0-<10.0</td> <td>110</td> <td>93,290</td> <td>0.87 (0.67-1.11)</td> <td>0.87 (0.67-1.12)</td> <td>0.91 (0.70-1.17)</td> </tr> <tr> <td>10.0-<18.5</td> <td>103</td> <td>96,592</td> <td>0.77 (0.60-1.00)</td> <td>0.77 (0.60-1.00)</td> <td>0.79 (0.61-1.02)</td> </tr> <tr> <td>18.5+</td> <td>106</td> <td>99,250</td> <td>0.78 (0.60-1.01)</td> <td>0.79 (0.61-1.03)</td> <td>0.83 (0.64-1.07)</td> </tr> <tr> <td></td> <td></td> <td></td> <td></td> <td>p-trend = 0.007</td> <td>p-trend = 0.13</td> </tr> <tr> <td colspan="6">Baseline sitting⁴ (hr/day)</td> </tr> <tr> <td><3</td> <td>195</td> <td>184,173</td> <td>1.00 (ref.)</td> <td>1.00 (ref.)</td> <td>1.00 (ref.)</td> </tr> <tr> <td>3-5</td> <td>203</td> <td>165,501</td> <td>1.13 (0.92-1.38)</td> <td>1.13 (0.92-1.38)</td> <td>1.02 (0.83-1.25)</td> </tr> <tr> <td>6+</td> <td>56</td> <td>36,584</td> <td>1.40 (1.04-1.89)</td> <td>1.40 (1.03-1.89)</td> <td>1.18 (0.87-1.59)</td> </tr> <tr> <td></td> <td></td> <td></td> <td></td> <td>p-trend = 0.05</td> <td>p-trend = 0.41</td> </tr> <tr> <td colspan="6">Exercise in 1982⁴</td> </tr> <tr> <td>None/Slight</td> <td>156</td> <td>105,260</td> <td>1.00 (ref.)</td> <td>1.00 (ref.)</td> <td>1.00 (ref.)</td> </tr> <tr> <td>Moderate</td> <td>285</td> <td>264,391</td> <td>0.71 (0.58-0.86)</td> <td>0.74 (0.60-0.90)</td> <td>0.83 (0.68-1.02)</td> </tr> <tr> <td>Heavy</td> <td>20</td> <td>20,608</td> <td>0.64 (0.40-1.02)</td> <td>0.67 (0.42-1.07)</td> <td>0.80 (0.50-1.28)</td> </tr> <tr> <td></td> <td></td> <td></td> <td></td> <td>p-trend = 0.003</td> <td>p-trend = 0.08</td> </tr> <tr> <td colspan="6">Recreational activity MET-hr/week at age 40⁴</td> </tr> <tr> <td>None</td> <td>64</td> <td>57,878</td> <td>0.91 (0.67-1.23)</td> <td>0.93 (0.68-1.26)</td> <td>0.92 (0.68-1.25)</td> </tr> <tr> <td>0<-<7</td> <td>119</td> <td>97,393</td> <td>1.00 (ref.)</td> <td>1.00 (ref.)</td> <td>1.00 (ref.)</td> </tr> <tr> <td>7-<17.5</td> <td>146</td> <td>115,712</td> <td>1.02 (0.80-1.30)</td> <td>1.02 (0.80-1.30)</td> <td>1.03 (0.81-1.32)</td> </tr> <tr> <td>17.5-<31.5</td> <td>78</td> <td>74,574</td> <td>0.84 (0.63-1.12)</td> <td>0.83 (0.65-1.11)</td> <td>0.81 (0.61-1.08)</td> </tr> <tr> <td>31.5-<42</td> <td>28</td> <td>20,991</td> <td>1.09 (0.73-1.65)</td> <td>1.11 (0.73-1.68)</td> <td>1.11 (0.73-1.68)</td> </tr> <tr> <td>42+</td> <td>25</td> <td>22,236</td> <td>0.92 (0.60-1.42)</td> <td>0.94 (0.61-1.45)</td> <td>0.96 (0.63-1.49)</td> </tr> <tr> <td></td> <td></td> <td></td> <td></td> <td>p-trend = 0.74</td> <td>p-trend = 0.72</td> </tr> <tr> <td colspan="6">Long-term exercise^{4,5}</td> </tr> <tr> <td>None/consistently low</td> <td>142</td> <td>90,185</td> <td>1.00 (ref.)</td> <td>1.00 (ref.)</td> <td>1.00 (ref.)</td> </tr> <tr> <td>Low 1982, High 1992</td> <td>14</td> <td>15,075</td> <td>0.58 (0.34-1.01)</td> <td>0.58 (0.34-1.01)</td> <td>0.65 (0.37-1.13)</td> </tr> <tr> <td>High 1982, Low 1992</td> <td>229</td> <td>203,277</td> <td>0.69 (0.56-0.86)</td> <td>0.72 (0.58-0.89)</td> <td>0.81 (0.65-1.00)</td> </tr> <tr> <td>Consistently high</td> <td>76</td> <td>81,722</td> <td>0.58 (0.44-0.76)</td> <td>0.61 (0.46-0.80)</td> <td>0.75 (0.56-0.99)</td> </tr> </tbody> </table> <p>¹Age-adjusted Hazard rate ratio and corresponding 95% confidence interval. ²Multivariate-adjusted RR and corresponding 95% CI adjusted for age, age at menarche, age at menopause, duration of OC use, parity, smoking, total caloric intake, personal history of diabetes and postmenopausal HT use. ³Multivariate-adjusted RR and corresponding 95% CI also adjusted for BMI. ⁴Numbers may not equal total due to missing information. ⁵Combination of exercise prospectively collected in 1982 and recreational physical activity at baseline 1992.</p> | | | | | | | | Cases | p-years | RR ¹ (95% CI) | RR ² (95% CI) | RR ³ (95% CI) | Baseline recreational activity MET-hr/week | | | | | | None | 43 | 34,622 | 0.92 (0.66-1.28) | 0.93 (0.67-1.30) | 0.84 (0.60-1.17) | 0<-<7 | 170 | 124,302 | 1.00 (ref.) | 1.00 (ref.) | 1.00 (ref.) | 7-<17.5 | 157 | 133,553 | 0.86 (0.69-1.07) | 0.86 (0.70-1.07) | 0.92 (0.74-1.14) | 17.5-<31.5 | 72 | 75,456 | 0.70 (0.53-0.92) | 0.70 (0.53-0.93) | 0.80 (0.60-1.05) | 31.5+ | 24 | 27,264 | 0.65 (0.42-1.00) | 0.67 (0.44-1.03) | 0.79 (0.52-1.22) | | | | | p-trend = 0.007 | p-trend = 0.18 | Baseline nonrecreational activity MET-hr/week ⁴ | | | | | | None | 11 | 5,473 | 1.45 (0.78-2.69) | 1.44 (0.78-2.66) | 1.31 (0.71-2.44) | >0-5.0 | 132 | 96,620 | 1.00 (ref.) | 1.00 (ref.) | 1.00 (ref.) | >5.0-<10.0 | 110 | 93,290 | 0.87 (0.67-1.11) | 0.87 (0.67-1.12) | 0.91 (0.70-1.17) | 10.0-<18.5 | 103 | 96,592 | 0.77 (0.60-1.00) | 0.77 (0.60-1.00) | 0.79 (0.61-1.02) | 18.5+ | 106 | 99,250 | 0.78 (0.60-1.01) | 0.79 (0.61-1.03) | 0.83 (0.64-1.07) | | | | | p-trend = 0.007 | p-trend = 0.13 | Baseline sitting ⁴ (hr/day) | | | | | | <3 | 195 | 184,173 | 1.00 (ref.) | 1.00 (ref.) | 1.00 (ref.) | 3-5 | 203 | 165,501 | 1.13 (0.92-1.38) | 1.13 (0.92-1.38) | 1.02 (0.83-1.25) | 6+ | 56 | 36,584 | 1.40 (1.04-1.89) | 1.40 (1.03-1.89) | 1.18 (0.87-1.59) | | | | | p-trend = 0.05 | p-trend = 0.41 | Exercise in 1982 ⁴ | | | | | | None/Slight | 156 | 105,260 | 1.00 (ref.) | 1.00 (ref.) | 1.00 (ref.) | Moderate | 285 | 264,391 | 0.71 (0.58-0.86) | 0.74 (0.60-0.90) | 0.83 (0.68-1.02) | Heavy | 20 | 20,608 | 0.64 (0.40-1.02) | 0.67 (0.42-1.07) | 0.80 (0.50-1.28) | | | | | p-trend = 0.003 | p-trend = 0.08 | Recreational activity MET-hr/week at age 40 ⁴ | | | | | | None | 64 | 57,878 | 0.91 (0.67-1.23) | 0.93 (0.68-1.26) | 0.92 (0.68-1.25) | 0<-<7 | 119 | 97,393 | 1.00 (ref.) | 1.00 (ref.) | 1.00 (ref.) | 7-<17.5 | 146 | 115,712 | 1.02 (0.80-1.30) | 1.02 (0.80-1.30) | 1.03 (0.81-1.32) | 17.5-<31.5 | 78 | 74,574 | 0.84 (0.63-1.12) | 0.83 (0.65-1.11) | 0.81 (0.61-1.08) | 31.5-<42 | 28 | 20,991 | 1.09 (0.73-1.65) | 1.11 (0.73-1.68) | 1.11 (0.73-1.68) | 42+ | 25 | 22,236 | 0.92 (0.60-1.42) | 0.94 (0.61-1.45) | 0.96 (0.63-1.49) | | | | | p-trend = 0.74 | p-trend = 0.72 | Long-term exercise ^{4,5} | | | | | | None/consistently low | 142 | 90,185 | 1.00 (ref.) | 1.00 (ref.) | 1.00 (ref.) | Low 1982, High 1992 | 14 | 15,075 | 0.58 (0.34-1.01) | 0.58 (0.34-1.01) | 0.65 (0.37-1.13) | High 1982, Low 1992 | 229 | 203,277 | 0.69 (0.56-0.86) | 0.72 (0.58-0.89) | 0.81 (0.65-1.00) | Consistently high | 76 | 81,722 | 0.58 (0.44-0.76) | 0.61 (0.46-0.80) | 0.75 (0.56-0.99) |
| | Cases | p-years | RR ¹ (95% CI) | RR ² (95% CI) | RR ³ (95% CI) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Baseline recreational activity MET-hr/week | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| None | 43 | 34,622 | 0.92 (0.66-1.28) | 0.93 (0.67-1.30) | 0.84 (0.60-1.17) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 0<-<7 | 170 | 124,302 | 1.00 (ref.) | 1.00 (ref.) | 1.00 (ref.) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 7-<17.5 | 157 | 133,553 | 0.86 (0.69-1.07) | 0.86 (0.70-1.07) | 0.92 (0.74-1.14) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 17.5-<31.5 | 72 | 75,456 | 0.70 (0.53-0.92) | 0.70 (0.53-0.93) | 0.80 (0.60-1.05) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 31.5+ | 24 | 27,264 | 0.65 (0.42-1.00) | 0.67 (0.44-1.03) | 0.79 (0.52-1.22) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | p-trend = 0.007 | p-trend = 0.18 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Baseline nonrecreational activity MET-hr/week ⁴ | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| None | 11 | 5,473 | 1.45 (0.78-2.69) | 1.44 (0.78-2.66) | 1.31 (0.71-2.44) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| >0-5.0 | 132 | 96,620 | 1.00 (ref.) | 1.00 (ref.) | 1.00 (ref.) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| >5.0-<10.0 | 110 | 93,290 | 0.87 (0.67-1.11) | 0.87 (0.67-1.12) | 0.91 (0.70-1.17) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 10.0-<18.5 | 103 | 96,592 | 0.77 (0.60-1.00) | 0.77 (0.60-1.00) | 0.79 (0.61-1.02) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 18.5+ | 106 | 99,250 | 0.78 (0.60-1.01) | 0.79 (0.61-1.03) | 0.83 (0.64-1.07) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | p-trend = 0.007 | p-trend = 0.13 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Baseline sitting ⁴ (hr/day) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <3 | 195 | 184,173 | 1.00 (ref.) | 1.00 (ref.) | 1.00 (ref.) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 3-5 | 203 | 165,501 | 1.13 (0.92-1.38) | 1.13 (0.92-1.38) | 1.02 (0.83-1.25) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 6+ | 56 | 36,584 | 1.40 (1.04-1.89) | 1.40 (1.03-1.89) | 1.18 (0.87-1.59) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | p-trend = 0.05 | p-trend = 0.41 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Exercise in 1982 ⁴ | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| None/Slight | 156 | 105,260 | 1.00 (ref.) | 1.00 (ref.) | 1.00 (ref.) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Moderate | 285 | 264,391 | 0.71 (0.58-0.86) | 0.74 (0.60-0.90) | 0.83 (0.68-1.02) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Heavy | 20 | 20,608 | 0.64 (0.40-1.02) | 0.67 (0.42-1.07) | 0.80 (0.50-1.28) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | p-trend = 0.003 | p-trend = 0.08 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Recreational activity MET-hr/week at age 40 ⁴ | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| None | 64 | 57,878 | 0.91 (0.67-1.23) | 0.93 (0.68-1.26) | 0.92 (0.68-1.25) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 0<-<7 | 119 | 97,393 | 1.00 (ref.) | 1.00 (ref.) | 1.00 (ref.) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 7-<17.5 | 146 | 115,712 | 1.02 (0.80-1.30) | 1.02 (0.80-1.30) | 1.03 (0.81-1.32) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 17.5-<31.5 | 78 | 74,574 | 0.84 (0.63-1.12) | 0.83 (0.65-1.11) | 0.81 (0.61-1.08) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 31.5-<42 | 28 | 20,991 | 1.09 (0.73-1.65) | 1.11 (0.73-1.68) | 1.11 (0.73-1.68) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 42+ | 25 | 22,236 | 0.92 (0.60-1.42) | 0.94 (0.61-1.45) | 0.96 (0.63-1.49) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | p-trend = 0.74 | p-trend = 0.72 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Long-term exercise ^{4,5} | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| None/consistently low | 142 | 90,185 | 1.00 (ref.) | 1.00 (ref.) | 1.00 (ref.) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Low 1982, High 1992 | 14 | 15,075 | 0.58 (0.34-1.01) | 0.58 (0.34-1.01) | 0.65 (0.37-1.13) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| High 1982, Low 1992 | 229 | 203,277 | 0.69 (0.56-0.86) | 0.72 (0.58-0.89) | 0.81 (0.65-1.00) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Consistently high | 76 | 81,722 | 0.58 (0.44-0.76) | 0.61 (0.46-0.80) | 0.75 (0.56-0.99) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 図表掲載箇所 | P1880, Table2 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 概要 (800字まで) | <p>本研究は、アメリカのCPS-II Nutrition Cohortに参加した閉経後女性42,672名を対象に11年間の追跡調査を行い、身体活動量と子宮内膜がん発症との関連を検討したものである。質問紙から、過去1年間の速歩、水泳、球技などの余暇時間身体活動、ガーデニング、掃除、修繕などの家事活動、テレビ視聴や座位などの不活動時間を尋ね、それぞれの活動をメッツ値に換算し身体活動量を算出した。余暇時間身体活動量が週当たり7メッツ時未満の集団と比較すると、活動量が増えるごとに子宮内膜がん発症リスクの減少傾向はあるものの、有意な差はみられなかった。家事活動も同様に、活動量と発症リスクに負の相関傾向がみられたが、有意ではなかった。不活動時間については、時間の延長とともに発症リスクの上昇傾向がみられたが、同様に有意ではなかった。研究開始時に運動頻度が低く、かつ、追跡調査期間中も頻度が低いと回答した集団と比較すると、研究開始時および追跡期間中継続して運動頻度の高かった集団で子宮内膜がん発症リスクの有意な低下がみられた(0.75(95%信頼区間:0.56-0.99))。また、肥満度の高い集団(BMI>=25)においては、週当たり17.5メッツ時以上の余暇時間身体活動を実施することで発症リスクを低減させることが明らかとなった(0.59(0.42-0.83))。</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 結論 (200字まで) | 閉経後の女性コホートにおいて、特に肥満傾向の集団では余暇時間身体活動の実施が子宮内膜がん発症リスクを低減させることが明らかとなった。 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| エキスパートによるコメント (200字まで) | 身体活動基準の策定に使用された研究である。肥満と身体活動が子宮内膜がんの発症及ぼす相互作用について検討した点に意義がある。 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

担当者 久保絵里子・村上晴香・宮地元彦

Cancer Epidemiology, Biomarkers & Prevention



Obesity, Recreational Physical Activity, and Risk of Pancreatic Cancer In a Large U.S. Cohort

Alpa V. Patel, Carmen Rodriguez, Leslie Bernstein, et al.

Cancer Epidemiol Biomarkers Prev 2005;14:459-466. Published online February 25, 2005.

Updated Version Access the most recent version of this article at:
[doi:10.1158/1055-9965.EPI-04-0583](https://doi.org/10.1158/1055-9965.EPI-04-0583)

Cited Articles This article cites 37 articles, 11 of which you can access for free at:
<http://cebp.aacrjournals.org/content/14/2/459.full.html#ref-list-1>

Citing Articles This article has been cited by 30 HighWire-hosted articles. Access the articles at:
<http://cebp.aacrjournals.org/content/14/2/459.full.html#related-urls>

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

**Reprints and
Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR
Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications
Department at permissions@aacr.org.

Obesity, Recreational Physical Activity, and Risk of Pancreatic Cancer In a Large U.S. Cohort

Alpa V. Patel,¹ Carmen Rodriguez,¹ Leslie Bernstein,² Ann Chao,¹ Michael J. Thun,¹ and Eugenia E. Calle¹

¹Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, Georgia and ²Department of Preventive Medicine, University of Southern California School of Medicine, Los Angeles, California

Abstract

Background: Obesity and physical activity, in part through their effects on insulin sensitivity, may be modifiable risk factors for pancreatic cancer.

Methods: The authors analyzed data from the American Cancer Society Cancer Prevention Study II Nutrition Cohort to examine the association between measures of adiposity, recreational physical activity, and pancreatic cancer risk. Information on current weight and weight at age 18, location of weight gain, and recreational physical activity were obtained at baseline in 1992 via a self-administered questionnaire for 145,627 men and women who were cancer-free at enrollment. During the 7 years of follow-up, 242 incident pancreatic cancer cases were identified among these participants. Cox proportional hazards modeling was used to compute hazard rate ratios (RR) and to adjust for potential confounding factors including personal history of diabetes and smoking.

Results: We observed an increased risk of pancreatic cancer among obese [body mass index (BMI) ≥ 30] men and women compared with men and women of normal BMI [< 25 ; RR, 2.08; 95% confidence interval (95% CI), 1.48-2.93, $P_{\text{trend}} = 0.0001$]. After adjustment for between BMI, risk of pancreatic cancer was independently increased among men and women who reported a tendency for central weight gain compared with men and women reporting a tendency for peripheral weight gain (RR, 1.45; 95% CI, 1.02-2.07). We observed no difference in pancreatic cancer incidence rates between men and women who were most active (> 31.5 metabolic equivalent hours per week) at baseline compared with men and women who reported no recreational physical activity (RR, 1.20; 95% CI, 0.63-2.27).

Conclusion: This study, along with several recent studies, supports the hypothesis that obesity and central adiposity are associated with pancreatic cancer risk. (Cancer Epidemiol Biomarkers Prev 2005;14(2):459-66)

Introduction

Pancreatic cancer is the fourth leading cancer cause of death among U.S. men and women (1). Over 31,000 new cases and an equal number of deaths due to pancreatic cancer are estimated to occur in 2004 (1). Cigarette smoking and diabetes are the only risk factors that have been consistently associated with pancreatic cancer (2-6). In addition, insulin resistance and abnormal glucose metabolism, without a diagnosis of diabetes, may also be risk factors in pancreatic cancer etiology (7-9). There is a direct relationship between body mass index (BMI) and insulin production, and there is sufficient evidence that obesity, especially intra-abdominal fat, is related to the development of insulin resistance (10). Physical activity may increase insulin sensitivity through reduction of intra-abdominal fat deposits; additionally, physical activity, independent of its effects on weight, has been associated with improved glucose metabolism, increased insulin sensitivity, and decreased plasma insulin levels (10). Therefore, we hypothesized that obesity, through BMI and abdominal weight gain, and physical activity may be modifiable risk factors for pancreatic cancer.

Results of previous observational studies on the association between obesity, physical activity, and pancreatic cancer risk have been inconsistent. Of the 20 studies (12 prospective cohorts, refs. 3, 7, 11-20; and eight case-control studies, refs. 21-28) that have reported on the association between BMI and pancreatic cancer risk, 10 report a positive association

(7, 11, 13, 16, 17, 19, 21-24) and 10 report no association (3, 5, 12, 14, 15, 18, 20, 25-28). Most early reports that observed no relationship between increasing BMI and risk of pancreatic cancer had limited power to examine a wide range of BMI (3, 15, 18, 20, 25-27), used proxy respondents for case patients (25-28), or did not adjust for important factors, such as smoking, that may significantly modify the association between obesity and pancreatic cancer risk (3, 18, 25, 27). However, more recent studies (since 1995), including a few large prospective cohorts, suggest that obese (BMI ≥ 30) individuals may have a higher risk of developing pancreatic cancer (11, 13, 16, 17, 19, 23, 24). One previous study (15) examined the association between pancreatic cancer risk and adult weight gain and reported a nonstatistically significant positive association. To our knowledge, no previous study has examined the association between location of weight gain and pancreatic cancer risk.

Of the seven studies (five prospective cohorts, refs. 3, 12, 14-16; two case-control studies, refs. 22, 29) that have reported on the association between recreational physical activity and pancreatic cancer, four studies found an inverse association (15, 16, 22, 29) and three found no association (3, 12, 14) between physical activity and pancreatic cancer risk. However, in most positive studies, a lower risk of pancreatic cancer generally was observed only with high levels of moderate to vigorous physical activity (15, 22, 29). Only one previous study (16), analyzing data from the Health Professionals Follow-up Cohort and Nurses' Health Study, observed a significant inverse association with moderate-intensity activities or walking/hiking for men and women; but this study found no association with vigorous activity. Consequently, the frequency, intensity, and type of physical activity necessary to influence pancreatic cancer risk remain unclear.

Received 8/3/04; revised 9/17/04; accepted 9/28/04.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Alpa V. Patel, Epidemiology and Surveillance Research, American Cancer Society, National Home Office, 1599 Clifton Road Northeast, Atlanta, GA 30329-4251. Phone: 1-404-329-7726; Fax: 1-404-327-6450. E-mail: apatel@cancer.org

Copyright © 2005 American Association for Cancer Research.

We examined the association of BMI, weight gain, location of weight gain, recreational physical activity, and risk of pancreatic cancer among men and women in the American Cancer Society Cancer Prevention Study II (CPS-II) Nutrition Cohort, a large prospective study in the United States. It should be noted that 38% of pancreatic cancer cases (49 cases in men and 44 cases in women) in this study were also included in the previous publication by Calle et al. (13) on obesity and cancer mortality using the larger CPS-II Mortality Cohort.

Materials and methods

Study Population. Men and women in this analysis were drawn from the 184,190 participants in the CPS-II Nutrition Cohort, which was established in 1992 by the American Cancer Society as a subgroup of the larger 1982 CPS-II baseline mortality cohort (30). Nearly all participants were ages 50 to 74 years at enrollment in 1992, and they completed a 10-page self-administered questionnaire that included questions on demographic, medical, reproductive, behavioral, environmental, and dietary factors. Beginning in 1997, follow-up questionnaires have been sent to cohort members every 2 years to update exposure information and to ascertain newly diagnosed cancers. Questionnaire response rates among living cohort members have been at least 90%. Cohort members who died are identified by routine linkage of the entire cohort with the National Death Index (31).

This analysis is based on 7 years of follow-up. We excluded participants who were lost to follow-up from 1992 to 1999 ($n = 8,223$), who reported prevalent cancer (except nonmelanoma skin cancer) at baseline ($n = 20,934$), who had missing or extreme (lowest and highest 0.1%) values of BMI ($n = 4,794$), who left the baseline recreational physical activity section blank ($n = 2,180$), or who had missing information on smoking status ($n = 1,575$). We also excluded individuals who died from any cause within the first year of follow-up to reduce the possibility of undiagnosed disease at baseline ($n = 852$) and those with an unverified date of diagnosis of pancreatic cancer ($n = 5$). After all exclusions, the final analytic cohort consisted of 145,627 men and women with a mean age at study entry of 62.9 years (± 6.4 SD).

Case Ascertainment. We identified a total of 242 incident pancreatic cancers that occurred between the date of enrollment and August 31, 1999, among those cohort members eligible for analysis. Seventy-nine percent of incident pancreatic cancers ($n = 190$) were initially identified through automated linkage of the cohort with the National Death Index where pancreatic cancer was listed as a primary or contributory cause of death (International Classification of Diseases, Ninth Revision codes 157 to 157.9 or International Classification of Diseases, Tenth Revision codes C25-C25.9; refs. 32, 33). Additional information for 141 of these interval deaths was obtained through linkage with state cancer registries. Pancreatic cancer cases ($n = 41$) were also initially identified by self-report on one of the two follow-up questionnaires (1997 and 1999) and subsequently verified by medical records ($n = 26$) or linkage with state cancer registries ($n = 15$). A previous study linking cohort participants with state cancer registries has shown that the Nutrition Cohort participants are highly accurate (93% sensitivity) in reporting any past cancer diagnoses (34). Finally, an additional 11 pancreatic cancer cases were reported by the participant as another cancer but were found to be pancreatic cancer upon examination of medical or registry records.

Measures of Obesity and Physical Activity. BMI (weight in kg/height in m^2) at baseline was calculated using self-reported weight and height and categorized as follows: 18.5 to 24.9, 25 to 29.9, and ≥ 30 . According to the WHO definition for obesity,

a BMI < 25 is considered "normal weight," 25 to 29.9 is "grade 1 overweight," 30 to 39.9 is "grade 2 overweight," and 40 or more is "grade 3 overweight" (35). In this analysis, we refer to BMI of 25 to 29.9 as "overweight" and BMI of ≥ 30 as "obese." We also categorized BMI at age 18 (using recalled weight at age 18 reported in 1992) as < 21 , 21 to 22.9, and ≥ 23 . BMI < 25 in 1992 and BMI < 21 at age 18 were the reference groups in their respective analyses.

We categorized adult weight change in kilograms (kg) between age 18 and weight at baseline and categorized as lost > 2.27 kg, lost 2.27 kg to gained 4.54 kg (reference group), gained 4.55 to 9.07 kg, gained 9.08 to 13.61 kg, and gained ≥ 13.62 kg. Lastly, we categorized location of weight gain using the question "When you gain weight, where on your body do you mainly add the weight: chest and shoulders, waist, hips and thighs, other part of the body, equally all over, or don't gain weight?" Central weight gain was defined as reported weight gain in chest and shoulders or waist, and peripheral weight gain was defined as reported weight gain in hips and thighs or equally all over. The vast majority of individuals categorized as central weight gainers reported weight gain on the waist only (84.2% of men and 80.3% of women), and a small percent of those included as central weight gainers gained weight on the waist and chest and shoulders (13.7% of men and 17.2% of women). Most men (95%) categorized as peripheral weight gainers reported weight gain equally all over, whereas reported weight gain in hips and thighs or equally all over was approximately equal in women categorized as peripheral weight gainers. Men and women with other responses that could not be clearly categorized into one of these two groups were excluded from analyses examining location of weight gain.

Baseline recreational physical activity information was collected using the question "During the past year, what was the average time per week you spent at the following kinds of activities: walking, jogging/running, lap swimming, tennis or racquetball, bicycling or stationary biking, aerobics/calisthenics, and dancing?" Response to each activity could be "none," "1 to 3 h/wk," "4 to 6 h/wk," or "7+ h/wk." Summary metabolic equivalent (MET) hours per week were calculated for each participant. A MET is the ratio of metabolic rate during a specific activity to resting metabolic rate (36). The summary MET score for each participant was calculated by multiplying the hours spent engaged in each activity (0 for none, 1 for 1-3 h/wk, 4 for 4-6 h/wk, and 7 for 7+ h/wk) times the MET score estimated for each activity according to the Compendium of Physical Activities (36). Due to the older age of this population, MET-hours per week were calculated using the lowest value in a category of hours spent and moderate intensity MET values for each activity to provide conservatively estimated summary measures. The following MET scores were used (36): 3.5 for walking, 7 for jogging/running, 7 for lap swimming, 6 for tennis or racquetball, 4 for bicycling/stationary biking, 4.5 for aerobics/calisthenics, and 3.5 for dancing.

In 1992, we also asked participants to recall recreational physical activity at age 40 based on the question, "At age 40, what was the average time per week you spent at the following kinds of activities: walking, jogging/running, lap swimming, tennis or racquetball, bicycling or stationary biking, aerobics/calisthenics, and dancing?" MET-hours per week at age 40 were then summarized using the same method as baseline recreational activity described above. Recreational physical activity at baseline and age 40 were categorized into MET-hours per week as none, > 0 to 7, > 7 to 17.5, > 17.5 to 31.5, or > 31.5 . People who reported no recreational physical activity were used as the reference group. Another measure of past physical activity was available using the historical 1982 CPS-II questionnaire data, where participants reported behavior 10 years before baseline. In 1982, participants were asked "How much exercise do you get (work or play): none, slight,

moderate, heavy?." Exercise in 1982 was categorized as none/slight, moderate, or heavy; people who responded "none" and "slight" were combined due to small numbers and were used as the reference group. Physical activity at age 40 (as recalled in 1992) and exercise reported in 1982 were combined with baseline 1992 exposure information to assess whether risk of pancreatic cancer was reduced among participants who consistently reported being physically active.

Statistical Analysis. We calculated age-standardized pancreatic cancer incidence rates for measures of obesity (BMI at baseline and age 18, adult weight gain, location of weight gain) and recreational physical activity (MET-hours in 1992 and age 40, exercise level in 1982) standardized to the sex-specific age distribution of CPS-II Nutrition Cohort participants. We used Cox proportional hazards modeling (37) to calculate hazards rate ratios (RR) and corresponding 95% confidence intervals (CI) to examine the relationship between measures of obesity, recreational physical activity, and pancreatic cancer. For each BMI and physical activity exposure variable, we assessed risk in two models, one adjusted only for age and the other adjusted for age and potential confounding factors. All Cox models were stratified on exact year of age at enrollment. Potential confounders included in the multivariate models smoking status (never, current, former) and time since quitting for former smokers (<10, 10-19, and >20 years), height (quintiles), alcohol intake (never, <1 drink per day, 1 drink per day, >1 drink per day, missing), education (\leq high school graduate, some college, college graduate and above, missing), first-degree family history of pancreatic cancer (yes, no), personal history of gallbladder disease (yes, no), personal history of diabetes at baseline (yes, no), total caloric intake (quartiles), fruit and vegetable intake (quartiles), and gender (male, female). Furthermore, all multivariate models were mutually adjusted for BMI and physical activity.

Trend tests for BMI, adult weight gain, and physical activity were conducted by assigning the mean BMI, weight change (in lb) or MET value, respectively, within each category to that category. To test whether any of the above-described potential confounders significantly modified the association between measures of obesity or recreational physical activity and pancreatic cancer risk, we constructed multiplicative interaction terms between each main exposure variable and all covariates. We also constructed interaction terms between measures of obesity and recreational physical activity to test for effect modification between these factors. Due to small numbers in some strata, categories of potential effect modifiers were collapsed. To test for any violation of the Cox proportional hazard assumption, we created interaction terms between measures of obesity and recreational physical activity with time. Statistical interaction and the Cox proportional hazard assumption were assessed in multivariate models using the likelihood ratio test and $P < 0.05$ was considered statistically significant (38).

Results

The mean baseline BMI in this study population was 26.4 (± 3.5 SD) among men and 25.6 (± 4.4 SD) among women. Thirty-five percent ($n = 34,734$) of men and 32% ($n = 24,582$) of women were overweight (BMI 25-29.9) and 14% ($n = 9,915$) of men and 15% ($n = 11,740$) of women were obese (BMI ≥ 30). Approximately 12% ($n = 8,345$) of men and 9% ($n = 6,908$) of women reported no recreational physical activity at baseline (Table 1). Among participants who reported any recreational physical activity at baseline, the median MET expenditure was 14 MET-h/wk for men and 9.5 MET-h/wk for women, which corresponds to ~ 4 and 3 hours, respectively, of moderately paced walking per week. Active participants at

all levels of MET expenditure engaged primarily in activities judged to be of low intensity (walking biking, aerobics/calisthenics, or dancing) rather than activities judged to be of moderate/high intensity (jogging/running, swimming, or tennis/racquetball). As expected, physical activity and body mass were inversely correlated, with physically active participants more likely to be leaner. Leaner and more physically active participants also were more likely to report being nonsmokers, not having gained weight since age 18 years, drink alcohol, have no history of diabetes, and have higher educational attainment.

Men and women with a BMI >30 had a relative risk of pancreatic cancer of 2.08 (95% CI 1.48-2.93, $P_{\text{trend}} = 0.0001$) compared with men and women of normal weight (Table 2). The association between BMI and pancreatic cancer risk was somewhat stronger in men (RR, 2.38; 95% CI, 1.50-3.78 for BMI ≥ 30 versus <25) than women (RR, 1.73; 95% CI, 1.02-2.92 for BMI ≥ 30 versus <25). Risk of pancreatic cancer was 33% higher among men and women who reported BMI >23 at age 18 compared with BMI <21 even after adjustment for baseline BMI in 1992 (RR, 1.33; 95% CI, 0.95-1.85, $P_{\text{trend}} = 0.11$).

After adjustment for baseline BMI, location of weight gain also was associated independently with risk of pancreatic cancer. Men and women who reported "central" weight gain had a relative risk of pancreatic cancer of 1.45 (95% CI, 1.02-2.07) compared with men and women who reported peripheral weight gain (Table 2). Similar to the observed BMI association, the risk was greater in men (RR, 1.51; 95% CI, 0.92-2.50) than in women (RR, 1.36; 95% CI, 0.80-2.30). We observed no independent association between adult weight change (age 18 to 1992) and pancreatic cancer in this population.

We observed no association between baseline recreational physical activity and risk of pancreatic cancer in this study. Men and women in the highest category of MET-hours per week (>31.5 MET-h/wk) had a relative risk of pancreatic cancer of 1.20 (95% CI, 0.63-2.27) compared with men and women who reported no physical activity at baseline (Table 3). Tests for trend including participants who reported no recreational physical activity ($P_{\text{trend}} = 0.97$) and excluding participants who reported no recreational physical activity ($P_{\text{trend}} = 0.82$) were not statistically significant. The lack of association also did not differ when we restricted the analysis to participants engaging in at least some moderate/heavy physical activity compared with those who reported no physical activity or only low-intensity physical activity (data not shown). We also examined the association between pancreatic cancer risk and recreational physical activity at age 40 (reported retrospectively at baseline). Physical activity at age 40 was not associated with risk of pancreatic cancer.

Additionally, we examined the association between pancreatic cancer risk and historically collected exercise levels reported in 1982. Moderate physical activity in 1982 was inversely associated with risk (RR, 0.74; 95% CI, 0.56-0.99; Table 3). Pancreatic cancer risk was not associated among individuals who reported being physically active across multiple time points compared with individuals who reported no recreational physical activity at each time point (data not shown). There also was no statistical interaction between measures of obesity and recreational physical activity levels.

We examined risk of pancreatic cancer in a stratified analysis by smoking status because residual confounding due to smoking has the potential to impact the relationship between BMI and pancreatic cancer risk (13). Risk of pancreatic cancer risk among men and women with BMI ≥ 30 compared with <25 was similar when restricting the analysis to never smokers (RR, 1.70; 95% CI, 0.95-3.06). Residual confounding by smoking in relation to BMI and pancreatic cancer risk in this cohort was minimal because there were few smokers. Only nine percent of cohort members reported smoking at baseline

Table 1. Selected study participant characteristics in relation to BMI and recreational physical activity at baseline among 145,627 men and women in the CPS-II Nutrition Cohort, 1992-1999

| Characteristic | BMI [weight (kg)/height (m) ²] | | | | | |
|---|--|---------------|---------------|---------------|---------------|---------------|
| | Men | | | Women | | |
| | <25 | 25 to <30 | 30+ | <25 | 25 to <30 | 30+ |
| No. participants | 24,940 | 34,734 | 9,915 | 39,716 | 24,582 | 11,740 |
| Age at baseline (mean ± SE) | 64.8 ± 0.04 | 63.6 ± 0.03 | 62.5 ± 0.06 | 62.1 ± 0.03 | 62.3 ± 0.04 | 61.3 ± 0.06 |
| Smoking status (%) | | | | | | |
| Never | 36.2 | 31.3 | 28.6 | 53.7 | 56.6 | 59 |
| Current | 10.7 | 8.3 | 7.6 | 9.6 | 7.7 | 5.6 |
| Former | 53.1 | 60.4 | 63.8 | 36.7 | 35.7 | 35.3 |
| MET-hours per week (mean ± SE) | 14.8 ± 0.08 | 13.0 ± 0.07 | 10.1 ± 0.13 | 13.4 ± 0.06 | 11.3 ± 0.08 | 9.3 ± 0.11 |
| Height, cm (mean ± SE) | 178.82 ± 0.05 | 178.31 ± 0.03 | 178.05 ± 0.08 | 164.34 ± 0.03 | 163.83 ± 0.05 | 162.56 ± 0.05 |
| Weight change, kg (age 18 to 1992; mean ± SE) | 7.89 ± 0.06 | 15.83 ± 0.06 | 27.12 ± 0.10 | 6.62 ± 0.04 | 16.69 ± 0.05 | 28.58 ± 0.07 |
| ≥College graduate, % | 53.9 | 45.3 | 35.6 | 35.6 | 28.2 | 24.3 |
| Family history of pancreatic cancer, % | 4.1 | 4.4 | 4.5 | 4.3 | 4.6 | 4.6 |
| Personal history of diabetes, % | 7.2 | 9.1 | 15.5 | 3.9 | 7 | 13.1 |
| Personal history of gallbladder disease, % | 6 | 8.3 | 10.5 | 10.2 | 17.4 | 26 |
| No alcohol intake in last year, % | 31.1 | 31.8 | 37.7 | 39.6 | 47.8 | 58.6 |
| Caloric intake, kcal (mean ± SE) | 1,754 ± 4 | 1,807 ± 3.4 | 1,911 ± 6.5 | 1,321 ± 2.5 | 1,379 ± 3.1 | 1,460 ± 4.5 |

| Characteristic | Recreational leisure-time activity (MET-hours per week) | | | | | |
|---|---|---------------|---------------|---------------|---------------|---------------|
| | Men | | | Women | | |
| | None | >0 to 17.5 | 17.5+ | None | >0 to 17.5 | 17.5+ |
| No. participants | 8,345 | 40,905 | 20,339 | 6,908 | 50,531 | 18,599 |
| Median MET-hours per week | 0 | 7.8 | 29.6 | 0 | 7.6 | 28.8 |
| Moderate/high-intensity activities,* % | — | 9.8 | 23.4 | — | 6.6 | 19.2 |
| Age at baseline (mean ± SE) | 63.4 ± 0.07 | 63.9 ± 0.03 | 64.3 ± 0.04 | 61.9 ± 0.08 | 62.0 ± 0.03 | 62.2 ± 0.05 |
| Smoking status (%) | | | | | | |
| Never | 25.9 | 33 | 34.6 | 51.6 | 56.9 | 52.9 |
| Current | 16.9 | 8.4 | 7 | 13.5 | 7.9 | 7.7 |
| Former | 57.1 | 58.6 | 58.3 | 34.9 | 35.2 | 39.4 |
| BMI [weight (kg)/height (m) ²]; mean ± SE | 27.2 ± 0.04 | 26.5 ± 0.02 | 26.0 ± 0.02 | 26.9 ± 0.05 | 25.7 ± 0.02 | 24.8 ± 0.03 |
| Height, cm (mean ± SE) | 178.31 ± 0.08 | 178.31 ± 0.03 | 178.56 ± 0.05 | 163.83 ± 0.08 | 163.83 ± 0.01 | 163.83 ± 0.05 |
| Weight change, kg (age 18 to 1992; mean ± SE) | 17.01 ± 0.12 | 15.01 ± 0.05 | 12.79 ± 0.08 | 16.60 ± 0.13 | 13.65 ± 0.05 | 10.98 ± 0.08 |
| ≥College graduate, % | 29.6 | 48.2 | 51.6 | 23.3 | 31.2 | 35.1 |
| Family history of pancreatic cancer, % | 4 | 4.3 | 4.5 | 4.5 | 4.4 | 4.4 |
| Personal history of diabetes, % | 11.1 | 9.4 | 8.5 | 8.4 | 6.3 | 5.7 |
| Personal history of gallbladder disease, % | 8.2 | 8 | 7.1 | 18 | 15.1 | 13.4 |
| No alcohol intake in last year, % | 40 | 32.2 | 29.8 | 53.8 | 46 | 40 |
| Caloric intake, kcal (mean ± SE) | 1,901 ± 7 | 1,770 ± 3.1 | 1,828 ± 4.5 | 1,379 ± 6 | 1,354 ± 2.2 | 1,374 ± 3.6 |

NOTE: All values (except age) are standardized to the age distribution of the study population.

*Low-intensity activities are defined as those with MET scores <4.5 (walking, biking, aerobics/calisthenics, or dancing), and moderate/high-intensity activities are defined as those with MET scores >4.5 (jogging/running, swimming, or tennis/racquetball).

and former smokers had a median of 22 years since quitting. There also was no statistical interaction between measures of obesity or baseline recreational physical activity and any of the other potential risk factors examined in this analysis (data not shown).

Discussion

Results from this prospective study support the hypothesis that obesity is associated with approximately a doubling of risk of pancreatic cancer. Higher risk of pancreatic cancer was observed among men and women with higher BMI at baseline and at age 18. The present findings also are consistent in direction and magnitude with six (7, 11, 13, 16, 17, 19) of twelve (3, 7, 11-20) prospective cohort studies, including results included in the large CPS-II Mortality Study (13), and four (21-24) of eight (21-28) case-control studies that found a positive association between BMI and pancreatic cancer risk. There are several possible explanations for the inconsistent findings of obesity and pancreatic cancer risk across previous studies. First, studies that observed a positive association generally examined higher levels of BMI (≥30) and had larger sample sizes (at least 10 cases in the highest BMI category). Seven (11, 13, 16, 17, 19, 23,

24) of eight (11, 13, 15-17) previous studies that examined an association with BMI of ≥30 found an increased risk of pancreatic cancer ranging from 20% to 180% (Fig. 1). The one previous study (15) that reported no association with BMI of ≥30 and pancreatic cancer risk had limited power with only four cases of pancreatic cancer classified as obese.

A second possible explanation for the lack of association observed in early case-control studies may be due to the use of proxy respondents. If proxy respondents systematically underreported weight for case patients, this would bias results toward the null. Four (21-24) of eight (21-28) case-control studies used only direct patient interviews, and all four studies found a positive association between BMI and pancreatic cancer risk. Third, many studies that did not observe an association with obesity also did not properly control for smoking history (3, 18, 25, 27). Residual confounding by smoking due to the lack of proper (or any) adjustment for smoking may bias the association between obesity and pancreatic cancer risk toward the null.

Our results also support a role of central adiposity, independent of BMI, on pancreatic cancer carcinogenesis, an association that previously has not been examined in observational studies. There is a direct linear relationship between intra-abdominal fat deposits, insulin production, and

Table 2. RR and 95% CI for measure of obesity at various times during a participant's lifetime and pancreatic cancer, CPS-II Nutrition Cohort, 1992-1999

| | BMI [weight (kg)/height (m) ²] at baseline (1992) | | | | | |
|------------------------------------|---|---------------------|------------------|-----------------------------|------------------|-----------------------------|
| | <25 | 25 to <30 | 30+ | <i>P</i> _{trend} * | | |
| Men | | | | | | |
| No. cases/person-years | 44/155,031 | 57/218,536 | 36/62,047 | | | |
| Age-standardized rate | 29.01 | 29 | 67.71 | | | |
| RR [‡] (95% CI) | 1 (reference) | 1.00 (0.67-1.48) | 2.43 (1.55-3.80) | | | |
| RR [§] (95% CI) | 1 (reference) | 0.99 (0.66-1.47) | 2.38 (1.50-3.78) | 0.0004 | | |
| Women | | | | | | |
| No. cases/person-years | 50/250,570 | 33/154,594 | 22/73,572 | | | |
| Age-standardized rate | 21.84 | 22.91 | 35.19 | | | |
| RR [‡] (95% CI) | 1 (reference) | 1.07 (0.69-1.66) | 1.66 (1.00-2.74) | | | |
| RR [§] (95% CI) | 1 (reference) | 1.09 (0.70-1.70) | 1.73 (1.02-2.92) | 0.06 | | |
| Men + women | | | | | | |
| RR [§] (95% CI) | 1 (reference) | 1.03 (0.76-1.38) | 2.08 (1.48-2.93) | 0.0001 | | |
| | BMI (weight (kg)/height (m) ²) at age 18 [¶] | | | | | |
| | <21 | 21 to <23 | 23+ | <i>P</i> _{trend} * | | |
| Men | | | | | | |
| No. cases/person-years | 48/175,978 | 32/117,073 | 56/136,460 | | | |
| Age-standardized rate [†] | 28.41 | 28.95 | 49.53 | | | |
| RR [‡] (95% CI) | 1 (reference) | 1.07 (0.68-1.67) | 1.70 (1.15-2.50) | | | |
| RR ^{§,**} | 1 (reference) | 1.06 (0.67-1.67) | 1.43 (0.94-2.19) | 0.09 | | |
| Women | | | | | | |
| No. cases/person-years | 59/294,896 | 25/107,363 | 17/71,824 | | | |
| Age-standardized rate [†] | 21.87 | 25.13 | 27.95 | | | |
| RR [‡] (95% CI) | 1 (reference) | 1.18 (0.74-1.88) | 1.25 (0.73-2.15) | | | |
| RR ^{§,**} (95% CI) | 1 (reference) | 1.15 (0.71-1.85) | 1.06 (0.59-1.89) | 0.77 | | |
| Men + women | | | | | | |
| RR ^{§ ,**} (95% CI) | 1 (reference) | 1.07 (0.77-1.49) | 1.33 (0.95-1.85) | 0.11 | | |
| | Adult weight change (age 18 to 1992) [¶] , kg | | | | | |
| | > -2.27 | -2.27 to +4.54 | +4.55 to +9.07 | +9.08 to +13.61 | +13.62 or more | <i>P</i> _{trend} * |
| Men | | | | | | |
| No. cases/person-years | 11/15,891 | 12/61,242 | 21/71,901 | 15/76,014 | 77/204,464 | |
| Age-standardized rate [†] | 75.48 | 20.97 | 31.55 | 22.98 | 40.64 | |
| RR [‡] (95% CI) | 3.67 (1.62-8.32) | 1 (reference) | 1.50 (0.74-3.04) | 1.02 (0.48-2.17) | 1.99 (1.08-3.65) | |
| RR ^{§,**} (95% CI) | 3.54 (1.56-8.03) | 1 (reference) | 1.49 (0.73-3.04) | 0.97 (0.45-2.11) | 1.59 (0.82-3.08) | 0.36 |
| Women | | | | | | |
| No. cases/person-years | 4/21,168 | 20/86,920 | 18/86,513 | 21/83,551 | 38/195,931 | |
| Age-standardized rate [†] | 19.80 | 25.11 | 21.93 | 28.42 | 21.70 | |
| RR [‡] (95% CI) | 0.79 (0.27-2.32) | 1 (reference) | 0.93 (0.49-1.75) | 1.12 (0.61-2.08) | 0.87 (0.50-1.49) | |
| RR [§] (95% CI) | 0.71 (0.24-2.08) | 1 (reference) | 0.89 (0.47-1.68) | 0.95 (0.50-1.80) | 0.50 (0.25-1) | 0.22 |
| Men + women | | | | | | |
| RR ^{† ,**} (95% CI) | 1.74 (0.94-3.22) | 1 (reference) | 1.12 (0.70-1.79) | 0.97 (0.60-1.58) | 0.96 (0.61-1.52) | 0.16 |
| | Location of weight gain ^{¶¶} | | | | | |
| | Peripheral weight gain | Central weight gain | | | | |
| Men | | | | | | |
| No. cases/person-years | 18/71,964 | 103/275,518 | | | | |
| Age-standardized rate [†] | 25.88 | 41.21 | | | | |
| RR [‡] (95% CI) | 1 (reference) | 1.53 (0.92-2.52) | | | | |
| RR ^{§,**} (95% CI) | 1 (reference) | 1.51 (0.92-2.50) | | | | |
| Women | | | | | | |
| No. cases/person-years | 38/193,587 | 24/86,474 | | | | |
| Age-standardized rate [†] | 24.17 | 27.76 | | | | |
| RR [‡] (95% CI) | 1 (reference) | 1.21 (0.73-2.02) | | | | |
| RR ^{§,**} (95% CI) | 1 (reference) | 1.36 (0.80-2.30) | | | | |
| Men + women | | | | | | |
| RR ^{§ ,**} (95% CI) | 1 (reference) | 1.45 (1.02-2.07) | | | | |

*Trend tests conducted in multivariate models.

†Age-standardized incidence rates per 100,000 standardized to the sex-specific distribution of Nutrition Cohort participants.

‡Age-adjusted RR and corresponding 95% CI.

§Multivariate-adjusted hazard RR and 95% CI adjusted for: age, smoking status, years since quitting smoking among former smokers, education, family history of pancreatic cancer, personal history of gallbladder disease, personal history of diabetes, height, total caloric intake, and MET-hours per week in 1992.

¶Also adjusted for gender.

¶One case in men (6,103 person-years) and four cases in women (4,653 person-years) not included due to missing BMI at age 18.

**Also adjusted for BMI in 1992.

¶¶Sixteen cases in men (88,132 person-years) and 43 cases in women (198,675 person-years) not included due to report of inconsistent or other locations of weight gain. Central weight gain defined as weight gain in "waist" or "chest and shoulders" and peripheral weight gain defined as "hips and thighs" or "equally all over."

Table 3. RR and 95% CI for measures of recreational physical activity at various points in time and pancreatic cancer, CPS-II Nutrition Cohort, 1992-1999

| | MET-hours per week (1992) | | | | | <i>P</i> _{trend} * |
|------------------------------------|--|------------------|------------------|-----------------------------|------------------|-----------------------------|
| | None | >0-7 | >7-17.5 | >17.5-31.5 | >31.5 | |
| Men | | | | | | |
| No. cases/person-years | 12/51,179 | 44/130,056 | 42/126,302 | 32/97,277 | 7/30,801 | |
| Age-standardized rate [†] | 27.97 | 37.33 | 36.35 | 33.95 | 24.11 | |
| RR [‡] (95% CI) | 1 (reference) | 1.39 (0.73-2.63) | 1.33 (0.70-2.53) | 1.29 (0.66-2.51) | 0.91 (0.36-2.30) | |
| RR [§] (95% CI) | 1 (reference) | 1.45 (0.76-2.75) | 1.43 (0.74-2.73) | 1.41 (0.72-2.77) | 1.01 (0.39-2.60) | 0.84 (0.52 among active) |
| Women | | | | | | |
| No. cases/person-years | 12/42,852 | 41/163,528 | 23/154,903 | 20/88,987 | 9/28,466 | |
| Age-standardized rate [†] | 35.10 | 28.22 | 15.33 | 22.55 | 35.49 | |
| RR [‡] (95% CI) | 1 (reference) | 0.89 (0.47-1.69) | 0.52 (0.26-1.05) | 0.78 (0.38-1.59) | 1.13 (0.48-2.69) | |
| RR [§] (95% CI) | 1 (reference) | 1 (0.52-1.91) | 0.62 (0.30-1.25) | 0.92 (0.44-1.89) | 1.42 (0.59-3.41) | 0.73 (0.65 among active) |
| Men + women | | | | | | |
| RR [§] | 1 (reference) | 1.24 (0.79-1.96) | 1 (0.62-1.61) | 1.17 (0.72-1.91) | 1.20 (0.63-2.27) | 0.97 (0.82 among active) |
| | MET-hours per week (age 40) [¶] | | | | | <i>P</i> _{trend} * |
| | None | >0-7 | >7-17.5 | >17.5-31.5 | >31.5 | |
| Men | | | | | | |
| No. cases/person-years | 22/72,196 | 37/109,549 | 29/99,756 | 36/94,278 | 12/54,225 | |
| Age-standardized rate [†] | 36.79 | 36.24 | 31.06 | 39.42 | 25.81 | |
| RR (95% CI) [‡] | 1 (reference) | 1.09 (0.64-1.85) | 0.94 (0.54-1.64) | 1.18 (0.69-2) | 0.70 (0.35-1.42) | |
| RR (95% CI) [§] | 1 (reference) | 1.09 (0.64-1.85) | 0.95 (0.54-1.65) | 1.19 (0.70-2.02) | 0.69 (0.34-1.41) | 0.40 (0.32 among active) |
| Women | | | | | | |
| No. cases/person-years | 16/68,685 | 37/138,625 | 23/130,086 | 16/83,851 | 11/49,870 | |
| Age-standardized rate [†] | 25.17 | 29.92 | 20.53 | 19.96 | 23.88 | |
| RR [‡] (95% CI) | 1 (reference) | 1.12 (0.62-2.02) | 0.76 (0.40-1.43) | 0.78 (0.39-1.55) | 0.94 (0.44-2.02) | |
| RR [§] (95% CI) | 1 (reference) | 1.15 (0.64-2.07) | 0.77 (0.41-1.46) | 0.77 (0.38-1.53) | 0.94 (0.44-2.03) | 0.38 (0.41 among active) |
| Men + women | | | | | | |
| RR [§] (95% CI) | 1 (reference) | 1.15 (0.78-1.70) | 0.88 (0.58-1.34) | 1.03 (0.67-1.56) | 0.81 (0.48-1.36) | 0.24 (0.19 among active) |
| | Exercise (1982)** | | | <i>P</i> _{trend} * | | |
| | None/slight | Moderate | Heavy | | | |
| Men | | | | | | |
| No. cases/person-years | 45/112,960 | 73/268,276 | 19/51,413 | | | |
| Age-standardized rate [†] | 48.71 | 28.86 | 36.57 | | | |
| RR [‡] (95% CI) | 1 (reference) | 0.62 (0.43-0.90) | 0.89 (0.52-1.52) | | | |
| RR [§] (95% CI) | 1 (reference) | 0.70 (0.48-1.02) | 1.12 (0.64-1.95) | 0.69 (0.75 among active) | | |
| Women | | | | | | |
| No. cases/person-years | 30/128,524 | 67/319,625 | 6/24,935 | | | |
| Age-standardized rate [†] | 27.53 | 22.55 | 24.77 | | | |
| RR [‡] (95% CI) | 1 (reference) | 0.79 (0.51-1.22) | 0.91 (0.38-2.18) | | | |
| RR [§] (95% CI) | 1 (reference) | 0.84 (0.54-1.29) | 0.97 (0.40-2.35) | 0.59 (0.43 among active) | | |
| Men + women | | | | | | |
| RR [§] (95% CI) | 1 (reference) | 0.74 (0.56-0.99) | 1.04 (0.65-1.65) | 0.38 (0.34 among active) | | |

*Trend tests conducted in multivariate models.

†Age-standardized incidence rates per 100,000 standardized to the sex-specific distribution of Nutrition Cohort participants.

‡Age-adjusted RR and corresponding 95% CI.

§Multivariate-adjusted hazard RR and 95% CI adjusted for: age, smoking status, years since quitting smoking among former smokers, education, family history of pancreatic cancer, personal history of gallbladder disease, personal history of diabetes, height, total caloric intake, and MET-hours per week in 1992.

||Also adjusted for gender.

¶One case in men (5,610 person-years) and two cases in women (7,618 person-years) not included due to missing information on physical activity at age 40.

**No cases in men (2,966 person-years) and two cases in women (5,652 person-years) not included due to missing 1982 exercise information.

the development of insulin resistance (reviewed in ref. 10). *In vitro* studies have shown that insulin binds to the insulin-like growth factor-I receptor and has growth-promoting effects in the pancreas (39). A hyperinsulinemic state also allows increased levels of insulin to pass through pancreatic exocrine cells, bind to the insulin receptor, and trigger mitotic activity (7, 9, 40). Increased insulin also can down-regulate insulin-like growth factor binding protein-I, leaving more bioavailable insulin-like growth factor-I that has been shown to *in vitro* stimulate cell proliferation (41, 42). As many women tend to gain weight more peripherally, the lack of or weaker magnitude of association observed in some studies in women compared with men (7, 17) may be explained by the role of central adiposity in pancreatic carcinogenesis.

In contrast with several previous studies, we did not observe a relationship between recreational physical activity

at baseline and pancreatic cancer risk. The low prevalence of high-intensity activities reported by participants in this cohort may account for the lack of an observed association. In this cohort, we could not examine the more vigorous physical activities that have been associated with reduced risk of pancreatic cancer in previous studies (15, 22, 29). The low-intensity physical activity reported by study participants may be insufficient to improve insulin sensitivity. It is also plausible that the lack of association in our study is due to the timing of the physical activity measure. Pancreatic cancer is generally diagnosed at advanced stages (1), and as a result of the relatively short follow-up period (7 years), pancreatic carcinogenesis may have been initiated before exposure assessment. We evaluated the association after excluding the first 2 years of follow-up and found no differences in risk estimates. Additionally, we evaluated pancreatic cancer risk according to




Figure 1. Previous studies (includes only studies with ≥ 10 cases in obese category) of obesity (BMI ≥ 30 or medical diagnosis) and pancreatic cancer risk.

physical activity in 1982 (10 years before baseline) due to the potential for change in physical activity in 1992 due to preclinical disease. We observed a 26% decrease in pancreatic cancer incidence among men and women engaging in moderate physical activity in 1982 compared with men and women engaging in no/slight physical activity in 1982. This finding is consistent with another large prospective cohort study that reported an association with moderate, but not vigorous, physical activity and pancreatic cancer risk (16). Thus, moderate physical activity may be inversely associated with pancreatic cancer risk.

There are a few limitations of our study that should be mentioned. In addition to the limited range of recreational physical activities commonly done by our participants, the lack of individual information on intensity of activities may increase the potential for misclassification of true energy expenditure. Another limitation is that obesity and physical activity measures are self-reported. Furthermore, our physical activity questions have not been validated but physical activity has been previously associated with breast (43) and colon cancer (44) in this cohort. Another limitation is the limited statistical power to examine detailed effect modification between BMI, central weight gain, recreational physical activity, and other covariates, such as smoking or personal history of diabetes. There are many strengths of this study that should also be noted. The prospective design eliminates differential reporting of past exposure information. We were able to control for potential confounding by most known or hypothesized pancreatic cancer risk factors. We had the ability to examine the association between adiposity and pancreatic cancer across a wide range of BMI.

In summary, we observed independent associations between both obesity and the tendency for central weight gain and pancreatic cancer risk. However, we did not observe an association between recreational physical activity and risk of pancreatic cancer in our population of elderly adults. Sufficient biological plausibility exists to warrant additional research to better understand the potential role of physical activity in pancreatic carcinogenesis and the amount, frequency, and intensity of physical activity needed to impact insulin response and other hormonal changes in relation to pancreatic cancer risk. Although evidence recognizing pancreatic cancer as

an obesity-related cancer previously has been considered insufficient (10), findings from this study, along with other recent studies, strongly support the role of obesity in pancreatic cancer development.

References

- American Cancer Society. Cancer facts and figures. Atlanta (GA): American Cancer Society; 2004.
- Coughlin S-S, Calle E-E, Patel A-V, Thun M-J. Predictors of pancreatic cancer mortality among a large cohort of United States adults. *Cancer Causes Control* 2000;11:915-23.
- Lund-Nilsen T-I, Vateen L-J. A prospective study of lifestyle factors and the risk of pancreatic cancer in Nord-Trøndelag, Norway. *Cancer Causes Control* 2000;11:645-52.
- Villeneuve P-J, Johnson K-C, Hanley A-J-G, Mao Y. Canadian Cancer Registries Epidemiology Research Group. Alcohol, tobacco, and coffee consumption and the risk of pancreatic cancer: results from the Canadian Enhanced Surveillance System case-control project. *Eur J Cancer Prev* 2000;9:49.
- Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. *JAMA* 1995;273:1605-9.
- Calle E-E, Murphy T-K, Rodriguez C, Thun M-J, Heath C-W Jr. Diabetes mellitus and pancreatic cancer mortality in a prospective cohort of United States adults. *Cancer Causes Control* 1998;9:403-10.
- Gapstur S-M, Gann P-H, Lowe W, Liu K, Colangelo L, Dyer A. Abnormal glucose metabolism and pancreatic cancer mortality. *JAMA* 2000;283:2552-8.
- McCarty M-F. Insulin secretion as a determinant of pancreatic cancer risk. *Med Hypotheses* 2001;57:146-50.
- Fisher W-E, Boros L-G, Schirmir W-J. Insulin promotes pancreatic cancer: evidence for endocrine influence on exocrine pancreatic tumors. *J Surg Res* 1996;63:310-3.
- IARC. IARC handbooks on cancer prevention: Weight control and physical activity. Lyon (France): IARC Press; 2002.
- Samanic C, Gridley G, Chow W, Lubin J, Hoover R-N, Fraumeni J-F. Obesity and cancer risk among white and black United States veterans. *Cancer Causes and Control* 2004;15:35-43.
- Lee I-M, Sesso H-D, Oguma Y, Paffenbarger R-S. Physical activity, body weight, and pancreatic cancer mortality. *Br J Cancer* 2003;88:679-83.
- Calle E-E, Rodriguez C, Walker-Thurmond K, Thun M-J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. *N Engl J Med* 2003;348:1625-38.
- Stolzenberg-Solomon R-Z, Pietinen P, Taylor P-R, Virtamo J, Albanes D. A prospective study of medical conditions, anthropometry, physical activity, and pancreatic cancer in male smokers (Finland). *Cancer Causes Control* 2002;13:417-26.
- Isaksson B, Jonsson F, Pedersen N-L, Larsson J, Feychting M, Permert J. Lifestyle factors and pancreatic cancer risk: a cohort study from the Swedish Twin Registry. *Int J Cancer* 2002;98:480-2.

16. Michaud D-S, Giovannucci E, Willett W-C, Colditz G-A, Stampfer M-J, Fuchs C-S. Physical activity, obesity, height, and the risk of pancreatic cancer. *JAMA* 2001;286:921-9.
17. Wolk A, Gridley G, Svensson M, Nyren O, McLaughlin J-K. A prospective study of obesity and cancer risk (Sweden). *Cancer Causes Control* 2001;12:13-21.
18. Shibata A, Mack T-M, Paganini-Hill A, Ross R-K, Henderson B-E. A prospective study of pancreatic cancer in the elderly. *Int J Cancer* 1994;58:46-9.
19. Moller H, Mellemegaard A, Lindvig K, Olsen J-H. Obesity and cancer risk: a Danish record-linkage study. *Eur J Cancer* 1994;30A:344-50.
20. Friedman G-D, Van Den Eeden S-K. Risk factors for pancreatic cancer: an exploratory study. *Int J Epidemiol* 1993;22:30-7.
21. Ji B-T, Hatch M-C, Chow W-H, et al. Anthropometric and reproductive factors and the risk of pancreatic cancer: a case-control study in Shanghai, China. *Int J Cancer* 1996;66:432-7.
22. Hanley A-J-G, Johnson K-C, Villeneuve P-J, Mao Y. Canadian Cancer Registries Epidemiology Research Group. Physical activity, anthropometric factors and risk of pancreatic cancer: results from the Canadian Enhanced Cancer Surveillance Program. *Int J Cancer* 2001;94:140-7.
23. Pan S-Y, Johnson K-C, Ugnat A, Wen S-W, Mao Y. The Canadian Cancer Registries Epidemiology Research Group. Association of obesity and cancer risk in Canada. *Am J Epidemiol* 2004;159:259-68.
24. Silverman D-T, Swanson C-A, Gridley G, et al. Dietary and nutritional factors and pancreatic cancer: a case-control study based on direct interviews. *J Natl Cancer Inst* 1998;90:1710-9.
25. Zatonski W, Przewozniak K, Howe G-R, Maisonneuve P, Walker A-M, Boyle P. Nutritional factors and pancreatic cancer: a case-control study from south-west Poland. *Int J Cancer* 1991;48:390-4.
26. Ghadirian P, Simard A, Baillargeon J, Maisonneuve P, Boyle P. Nutritional factors and pancreatic cancer in the Francophone community in Montreal, Canada. *Int J Cancer* 1991;47:1-6.
27. Howe G-R, Jain M, Miller A-B. Dietary factors and risk of pancreatic cancer: results of a Canadian population-based case-control study. *Int J Cancer* 1990;45:604-8.
28. Bueno De Mesquita H-B, Moerman C-J, Runia S, Maisonneuve P. Are energy and energy-providing nutrients related to exocrine carcinoma of the pancreas? *Int J Cancer* 1990;46:435-44.
29. Inoue M, Tajima K, Takezaki T, et al. Epidemiology of pancreatic cancer in Japan: a nested case-control study from the Hospital-based Epidemiologic Research Program at Aichi Cancer Center (HERPACC). *Int J Epidemiol* 2003;32:257-62.
30. Calle E-E, Rodriguez C, Jacobs E-J, et al. The American Cancer Society Cancer Prevention Study II Nutrition Cohort—rational, study design, and baseline characteristics. *Cancer* 2002;94:500-11.
31. Calle E-E, Terrell D-D. Utility of the National Death Index for ascertainment of mortality among Cancer Prevention Study II participants. *Am J Epidemiol* 1993;137:235-41.
32. WHO. International classification of diseases ninth revision. Manual of the international statistical classification of disease, injuries, and causes of death. 1. Geneva: WHO; 1977.
33. WHO. International statistical classification of diseases and related health problems tenth revision. 1. Geneva: WHO; 1992.
34. Bergmann M, Calle E, Mervis C, Miracle-McMahill H, Thun M, Heath C Jr. Validity of self-reported cancers in a prospective cohort study in comparison to data from state cancer registries. *Am J Epidemiol* 1998;147:556-62.
35. WHO. Physical status: the use and interpretation of anthropometry: report of a WHO Expert Committee 1995;854:1-452.
36. Ainsworth B-E, Haskell W-L, Leon A-S, et al. Compendium of physical activities: classification of energy costs of human physical activities. *Med Sci Sports Exerc* 1993;25:71-80.
37. Cox D. Regression models and life tables. *J R Stat Soc* 1972;34:187-220.
38. Kleinbaum G, Kupper L, Morgenstern H. Epidemiologic research: principles and quantitative methods. New York: Van Nostrand Reinhold Co.; 1982.
39. LeRoith D. Seminars in medicine of the Beth Israel Deaconess Medical Center: insulin-like growth factors. *N Engl J Med* 1997;336:633-40.
40. Williams J-A, Goldfine I-D. The insulin-pancreatic acinar axis. *Diabetes* 1985;34:980-6.
41. McCarty M-F. Up-regulation of IGF binding protein-1 as an anticarcinogenic strategy: relevance to caloric restriction, exercise, and insulin resistance. *Med Hypotheses* 1997;48:297-308.
42. Conover C-A, Lee P-D-K, Kanaley J-A, Clarkson J-T, Jensen M-D. Insulin regulation of insulin-like growth factor binding protein-1 in obese and nonobese humans. *J Clin Endocrinol Metab* 1992;74:1355-60.
43. Patel A-V, Calle E-E, Bernstein L, Wu A-H, Thun M-J. Recreational physical activity and risk of postmenopausal breast cancer in a large cohort of US women. *Cancer Causes Control* 2003;14:519-29.
44. Chao A, Connell C-J, Jacobs E-J, et al. Amount, intensity, and timing of recreational physical activity in relation to colon and rectal cancer in older adults—The Cancer Prevention Study II Nutrition Cohort. *Cancer Epidemiol Biomarkers Prev* 2004;13(12):2187-95.

| 論文名 | Obesity, recreational physical activity, and risk of pancreatic cancer in a large U.S. Cohort. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|------------------------------------|---|------------------|------------------|------------------|------------------|--|--------|--|---------------------------|--|--|--|--|--|------|------|---------|------------|-------|------------|--|--|--|--|--|--|------------------------|-----------|------------|------------|-----------|----------|--|------------------------------------|-------|-------|-------|-------|-------|--|--------------------------|---------------|------------------|------------------|------------------|------------------|--|--------------------------|---------------|------------------|------------------|------------------|------------------|--------------------------|--------------|--|--|--|--|--|--|------------------------|-----------|------------|------------|-----------|----------|--|------------------------------------|-------|-------|-------|-------|-------|--|--------------------------|---------------|------------------|------------------|------------------|------------------|--|--------------------------|---------------|---------------|------------------|------------------|------------------|--------------------------|-------------|---------------|------------------|---------------|------------------|------------------|--------------------------|-----------------|--|--|--|--|--|--|------------------------------------|--|--|--|--|--|--|--|-------------|----------|-------|--|--|--|------------|--|--|--|--|--|--|------------------------|-----------|------------|-----------|-----------|-----------|--|------------------------------------|-------|-------|-------|-------|-------|--|--------------------------|---------------|------------------|------------------|---------------|------------------|--|--------------------------|---------------|------------------|------------------|------------------|------------------|--------------------------|--------------|--|--|--|--|--|--|------------------------|-----------|------------|------------|-----------|-----------|--|------------------------------------|-------|-------|-------|-------|-------|--|--------------------------|---------------|------------------|------------------|------------------|------------------|--|--------------------------|---------------|------------------|------------------|------------------|------------------|--------------------------|-------------|---------------|------------------|------------------|------------------|------------------|--------------------------|--------------------------|--|--|--|--|--|--|
| 著者 | Patel AV, Rodriguez C, Bernstein L, Chao A, Thun MJ, Calle EE. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 雑誌名 | Cancer Epidemiol Biomarkers Prev | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 巻・号・頁 | 14(2) 459-66 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 発行年 | 2005 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| PubMedリンク | http://www.ncbi.nlm.nih.gov/pubmed/15734973 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 対象の内訳 | | ヒト | 動物 | 地域 | 欧米 | 研究の種類 | 縦断研究 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 対象 | 一般健常者 | 空白 | | () | | コホート研究 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 性別 | 男女混合 | () | | () | | () | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 年齢 | 62.9歳 | | | () | | 前向き研究 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 対象数 | 10000以上 | 空白 | | () | | () | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 調査の方法 | 質問紙 | () | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| アウトカム | 予防 | なし | なし | ガン予防 | なし | () | () | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 維持・改善 | なし | なし | なし | なし | () | () | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 図表 | <p>Table 3. RR and 95% CI for measures of recreational physical activity at various points in time and pancreatic cancer, CPS-II Nutrition Cohort, 1992-1999</p> <table border="1"> <thead> <tr> <th rowspan="2"></th> <th colspan="5">MET-hours per week (1992)</th> <th rowspan="2"><i>P</i>_{trend}^a</th> </tr> <tr> <th>None</th> <th>>0-7</th> <th>>7-17.5</th> <th>>17.5-31.5</th> <th>>31.5</th> </tr> </thead> <tbody> <tr> <td colspan="7">Men</td> </tr> <tr> <td>No. cases/person-years</td> <td>12/51,179</td> <td>44/130,056</td> <td>42/126,302</td> <td>32/97,277</td> <td>7/30,801</td> <td></td> </tr> <tr> <td>Age-standardized rate^b</td> <td>27.97</td> <td>37.33</td> <td>36.33</td> <td>33.95</td> <td>24.11</td> <td></td> </tr> <tr> <td>RR^c (95% CI)</td> <td>1 (reference)</td> <td>1.39 (0.73-2.63)</td> <td>1.33 (0.70-2.53)</td> <td>1.29 (0.66-2.51)</td> <td>0.91 (0.36-2.30)</td> <td></td> </tr> <tr> <td>RR^d (95% CI)</td> <td>1 (reference)</td> <td>1.45 (0.76-2.75)</td> <td>1.43 (0.74-2.73)</td> <td>1.41 (0.72-2.77)</td> <td>1.01 (0.39-2.61)</td> <td>0.84 (0.52 among active)</td> </tr> <tr> <td colspan="7">Women</td> </tr> <tr> <td>No. cases/person-years</td> <td>12/42,852</td> <td>41/163,528</td> <td>23/154,903</td> <td>20/88,987</td> <td>9/28,466</td> <td></td> </tr> <tr> <td>Age-standardized rate^b</td> <td>35.10</td> <td>28.22</td> <td>15.33</td> <td>22.55</td> <td>35.49</td> <td></td> </tr> <tr> <td>RR^c (95% CI)</td> <td>1 (reference)</td> <td>0.89 (0.47-1.69)</td> <td>0.52 (0.26-1.05)</td> <td>0.78 (0.38-1.59)</td> <td>1.13 (0.48-2.69)</td> <td></td> </tr> <tr> <td>RR^d (95% CI)</td> <td>1 (reference)</td> <td>1 (0.52-1.91)</td> <td>0.62 (0.30-1.25)</td> <td>0.92 (0.44-1.89)</td> <td>1.42 (0.59-3.41)</td> <td>0.73 (0.65 among active)</td> </tr> <tr> <td>Men + women</td> <td>1 (reference)</td> <td>1.24 (0.79-1.96)</td> <td>1 (0.62-1.61)</td> <td>1.17 (0.72-1.91)</td> <td>1.20 (0.63-2.27)</td> <td>0.97 (0.82 among active)</td> </tr> <tr> <td>RR^d</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td colspan="7">Exercise (1982)^e</td> </tr> <tr> <td></td> <td>None/slight</td> <td>Moderate</td> <td>Heavy</td> <td colspan="2"></td> <td><i>P</i>_{trend}^a</td> </tr> <tr> <td colspan="7">Men</td> </tr> <tr> <td>No. cases/person-years</td> <td>22/72,196</td> <td>37/109,549</td> <td>29/99,756</td> <td>36/94,278</td> <td>12/54,225</td> <td></td> </tr> <tr> <td>Age-standardized rate^b</td> <td>36.79</td> <td>36.24</td> <td>31.06</td> <td>39.42</td> <td>28.81</td> <td></td> </tr> <tr> <td>RR^c (95% CI)</td> <td>1 (reference)</td> <td>1.09 (0.64-1.85)</td> <td>0.94 (0.54-1.64)</td> <td>1.18 (0.69-2)</td> <td>0.79 (0.35-1.42)</td> <td></td> </tr> <tr> <td>RR^d (95% CI)</td> <td>1 (reference)</td> <td>1.09 (0.64-1.85)</td> <td>0.95 (0.54-1.65)</td> <td>1.19 (0.70-2.02)</td> <td>0.89 (0.34-1.41)</td> <td>0.40 (0.32 among active)</td> </tr> <tr> <td colspan="7">Women</td> </tr> <tr> <td>No. cases/person-years</td> <td>16/68,685</td> <td>37/138,625</td> <td>23/130,886</td> <td>16/83,851</td> <td>11/49,870</td> <td></td> </tr> <tr> <td>Age-standardized rate^b</td> <td>25.17</td> <td>28.92</td> <td>20.53</td> <td>19.96</td> <td>23.88</td> <td></td> </tr> <tr> <td>RR^c (95% CI)</td> <td>1 (reference)</td> <td>1.12 (0.62-2.02)</td> <td>0.76 (0.40-1.43)</td> <td>0.78 (0.38-1.55)</td> <td>0.94 (0.44-2.02)</td> <td></td> </tr> <tr> <td>RR^d (95% CI)</td> <td>1 (reference)</td> <td>1.15 (0.64-2.07)</td> <td>0.77 (0.41-1.48)</td> <td>0.77 (0.38-1.53)</td> <td>0.94 (0.44-2.03)</td> <td>0.38 (0.41 among active)</td> </tr> <tr> <td>Men + women</td> <td>1 (reference)</td> <td>1.15 (0.78-1.70)</td> <td>0.88 (0.58-1.34)</td> <td>1.03 (0.67-1.56)</td> <td>0.81 (0.48-1.36)</td> <td>0.24 (0.19 among active)</td> </tr> <tr> <td>RR^d (95% CI)</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> </tbody> </table> <p>^aTrend tests conducted in multivariate models. ^bAge-standardized incidence rates per 100,000 standardized to the sex-specific distribution of Nutrition Cohort participants. ^cAge-adjusted RR and corresponding 95% CI. ^dMultivariate-adjusted hazard RR and 95% CI adjusted for: age, smoking status, years since quitting smoking among former smokers, education, family history of pancreatic cancer, personal history of gallbladder disease, personal history of diabetes, height, total caloric intake, and MET-hours per week in 1992. ^eAlso adjusted for gender. ^fOne case in men (3.61 person-years) and two cases in women (2.68 person-years) not included due to missing information on physical activity at age 40. ^gNo cases in men (2.96 person-years) and two cases in women (6.92 person-years) not included due to missing 1982 exercise information.</p> | | | | | | | | MET-hours per week (1992) | | | | | <i>P</i> _{trend} ^a | None | >0-7 | >7-17.5 | >17.5-31.5 | >31.5 | Men | | | | | | | No. cases/person-years | 12/51,179 | 44/130,056 | 42/126,302 | 32/97,277 | 7/30,801 | | Age-standardized rate ^b | 27.97 | 37.33 | 36.33 | 33.95 | 24.11 | | RR ^c (95% CI) | 1 (reference) | 1.39 (0.73-2.63) | 1.33 (0.70-2.53) | 1.29 (0.66-2.51) | 0.91 (0.36-2.30) | | RR ^d (95% CI) | 1 (reference) | 1.45 (0.76-2.75) | 1.43 (0.74-2.73) | 1.41 (0.72-2.77) | 1.01 (0.39-2.61) | 0.84 (0.52 among active) | Women | | | | | | | No. cases/person-years | 12/42,852 | 41/163,528 | 23/154,903 | 20/88,987 | 9/28,466 | | Age-standardized rate ^b | 35.10 | 28.22 | 15.33 | 22.55 | 35.49 | | RR ^c (95% CI) | 1 (reference) | 0.89 (0.47-1.69) | 0.52 (0.26-1.05) | 0.78 (0.38-1.59) | 1.13 (0.48-2.69) | | RR ^d (95% CI) | 1 (reference) | 1 (0.52-1.91) | 0.62 (0.30-1.25) | 0.92 (0.44-1.89) | 1.42 (0.59-3.41) | 0.73 (0.65 among active) | Men + women | 1 (reference) | 1.24 (0.79-1.96) | 1 (0.62-1.61) | 1.17 (0.72-1.91) | 1.20 (0.63-2.27) | 0.97 (0.82 among active) | RR ^d | | | | | | | Exercise (1982)^e | | | | | | | | None/slight | Moderate | Heavy | | | <i>P</i> _{trend} ^a | Men | | | | | | | No. cases/person-years | 22/72,196 | 37/109,549 | 29/99,756 | 36/94,278 | 12/54,225 | | Age-standardized rate ^b | 36.79 | 36.24 | 31.06 | 39.42 | 28.81 | | RR ^c (95% CI) | 1 (reference) | 1.09 (0.64-1.85) | 0.94 (0.54-1.64) | 1.18 (0.69-2) | 0.79 (0.35-1.42) | | RR ^d (95% CI) | 1 (reference) | 1.09 (0.64-1.85) | 0.95 (0.54-1.65) | 1.19 (0.70-2.02) | 0.89 (0.34-1.41) | 0.40 (0.32 among active) | Women | | | | | | | No. cases/person-years | 16/68,685 | 37/138,625 | 23/130,886 | 16/83,851 | 11/49,870 | | Age-standardized rate ^b | 25.17 | 28.92 | 20.53 | 19.96 | 23.88 | | RR ^c (95% CI) | 1 (reference) | 1.12 (0.62-2.02) | 0.76 (0.40-1.43) | 0.78 (0.38-1.55) | 0.94 (0.44-2.02) | | RR ^d (95% CI) | 1 (reference) | 1.15 (0.64-2.07) | 0.77 (0.41-1.48) | 0.77 (0.38-1.53) | 0.94 (0.44-2.03) | 0.38 (0.41 among active) | Men + women | 1 (reference) | 1.15 (0.78-1.70) | 0.88 (0.58-1.34) | 1.03 (0.67-1.56) | 0.81 (0.48-1.36) | 0.24 (0.19 among active) | RR ^d (95% CI) | | | | | | |
| | MET-hours per week (1992) | | | | | <i>P</i> _{trend} ^a | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | None | >0-7 | >7-17.5 | >17.5-31.5 | >31.5 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Men | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| No. cases/person-years | 12/51,179 | 44/130,056 | 42/126,302 | 32/97,277 | 7/30,801 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Age-standardized rate ^b | 27.97 | 37.33 | 36.33 | 33.95 | 24.11 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| RR ^c (95% CI) | 1 (reference) | 1.39 (0.73-2.63) | 1.33 (0.70-2.53) | 1.29 (0.66-2.51) | 0.91 (0.36-2.30) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| RR ^d (95% CI) | 1 (reference) | 1.45 (0.76-2.75) | 1.43 (0.74-2.73) | 1.41 (0.72-2.77) | 1.01 (0.39-2.61) | 0.84 (0.52 among active) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Women | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| No. cases/person-years | 12/42,852 | 41/163,528 | 23/154,903 | 20/88,987 | 9/28,466 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Age-standardized rate ^b | 35.10 | 28.22 | 15.33 | 22.55 | 35.49 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| RR ^c (95% CI) | 1 (reference) | 0.89 (0.47-1.69) | 0.52 (0.26-1.05) | 0.78 (0.38-1.59) | 1.13 (0.48-2.69) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| RR ^d (95% CI) | 1 (reference) | 1 (0.52-1.91) | 0.62 (0.30-1.25) | 0.92 (0.44-1.89) | 1.42 (0.59-3.41) | 0.73 (0.65 among active) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Men + women | 1 (reference) | 1.24 (0.79-1.96) | 1 (0.62-1.61) | 1.17 (0.72-1.91) | 1.20 (0.63-2.27) | 0.97 (0.82 among active) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| RR ^d | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Exercise (1982)^e | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | None/slight | Moderate | Heavy | | | <i>P</i> _{trend} ^a | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Men | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| No. cases/person-years | 22/72,196 | 37/109,549 | 29/99,756 | 36/94,278 | 12/54,225 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Age-standardized rate ^b | 36.79 | 36.24 | 31.06 | 39.42 | 28.81 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| RR ^c (95% CI) | 1 (reference) | 1.09 (0.64-1.85) | 0.94 (0.54-1.64) | 1.18 (0.69-2) | 0.79 (0.35-1.42) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| RR ^d (95% CI) | 1 (reference) | 1.09 (0.64-1.85) | 0.95 (0.54-1.65) | 1.19 (0.70-2.02) | 0.89 (0.34-1.41) | 0.40 (0.32 among active) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Women | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| No. cases/person-years | 16/68,685 | 37/138,625 | 23/130,886 | 16/83,851 | 11/49,870 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Age-standardized rate ^b | 25.17 | 28.92 | 20.53 | 19.96 | 23.88 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| RR ^c (95% CI) | 1 (reference) | 1.12 (0.62-2.02) | 0.76 (0.40-1.43) | 0.78 (0.38-1.55) | 0.94 (0.44-2.02) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| RR ^d (95% CI) | 1 (reference) | 1.15 (0.64-2.07) | 0.77 (0.41-1.48) | 0.77 (0.38-1.53) | 0.94 (0.44-2.03) | 0.38 (0.41 among active) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Men + women | 1 (reference) | 1.15 (0.78-1.70) | 0.88 (0.58-1.34) | 1.03 (0.67-1.56) | 0.81 (0.48-1.36) | 0.24 (0.19 among active) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| RR ^d (95% CI) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 図表掲載箇所 | P464, Table 3 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 概要 (800字まで) | <p>The American Cancer Society Cancer Prevention Study II Nutrition Cohortに参加している145627名の男女を7年間追跡し、肥満や余暇時間における身体活動と膵臓がん発症との関連について検討した論文である。身体活動は、週当たりの次のような活動の実施時間が調査された。ウォーキング、ジョギング/ランニング、水泳、テニス/ラケットボール、自転車、エアロビクス、ダンス。これら余暇時間における身体活動をメッツ・時/週にて評価した。身体活動を全く行っていない群と比較して、0-7, 7-17.5, 17.5-31.5, 31.5メッツ・時/週以上行っている群では、すい臓がんになるリスクがそれぞれ、1.24(0.79-1.96), 1.0(0.62-1.61), 1.17(0.72-1.91), 1.20(0.63-2.27)であり、有意なリスク低下は認められなかった。一方、肥満に関しては、BMI25以上あることで、リスクの増加が認められた。</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 結論 (200字まで) | <p>身体活動の実施は、すい臓がんの発症と関連は認められなかったが、肥満はすい臓がんの発症と関連していることが明らかとなった。</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| エキスパートによるコメント (200字まで) | <p>すい臓がんに対する身体活動の予防的効果については、未だ結論が得られていない。本研究では、身体活動との関連が認められなかったが、関連があると報告するものもあるため、今後、強度や種類といったより詳細な検討が必要であろう。</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

担当者 村上晴香

Cancer Epidemiology, Biomarkers & Prevention



Recreational Physical Activity and Risk of Prostate Cancer in a Large Cohort of U.S. Men

Alpa V. Patel, Carmen Rodriguez, Eric J. Jacobs, et al.

Cancer Epidemiol Biomarkers Prev 2005;14:275-279. Published online January 24, 2005.

Updated Version Access the most recent version of this article at:
<http://cebp.aacrjournals.org/content/14/1/275>

Cited Articles This article cites 28 articles, 13 of which you can access for free at:
<http://cebp.aacrjournals.org/content/14/1/275.full.html#ref-list-1>

Citing Articles This article has been cited by 10 HighWire-hosted articles. Access the articles at:
<http://cebp.aacrjournals.org/content/14/1/275.full.html#related-urls>

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.

*Short Communication***Recreational Physical Activity and Risk of Prostate Cancer in a Large Cohort of U.S. Men**

Alpa V. Patel, Carmen Rodriguez, Eric J. Jacobs, Laura Solomon, Michael J. Thun, and Eugenia E. Calle

Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, Georgia

Abstract

Physical activity has been proposed as a modifiable risk factor for prostate cancer because of its potential effects on circulating hormones such as testosterone and insulin. We examined the association of various measures of physical activity with prostate cancer risk among men in the American Cancer Society Cancer Prevention Study II Nutrition Cohort, a large prospective study of U.S. adults. Information on recreational physical activity was obtained from a self-administered questionnaire completed at cohort enrollment in 1992/1993, as well as from a questionnaire completed as part of an earlier study in 1982. During the 9-year prospective follow-up, 5,503 incident prostate cancer cases were identified among 72,174 men who were cancer-free at enrollment. Cox proportional hazards modeling was used to compute hazard rate ratios (RR) for measures of recreational physical activity and to adjust for potential confounding factors. We observed no difference in risk of prostate cancer between men who engaged in the highest

level of recreational physical activity (>35 metabolic equivalent-hours/wk) and those who reported no recreational physical activity at baseline (RR, 0.90; 95% confidence interval, 0.78-1.04; *P* for trend = 0.31). We also did not observe an association between prostate cancer and recalled physical activity at age 40 or exercise reported in 1982. However, the incidence of aggressive prostate cancer was inversely associated with >35 metabolic equivalent-hours/wk of recreational physical activity compared with that in men who reported no recreational physical activity (RR, 0.69; 95% confidence interval, 0.52-0.92; *P* for trend = 0.06). Our findings are consistent with most previous studies that found no association between recreational physical activity and overall prostate cancer risk but suggest physical activity may be associated with reduced risk of aggressive prostate cancer. (Cancer Epidemiol Biomarkers Prev 2005;14(1):275-9)

Introduction

Prostate cancer is the leading cause of cancer incidence and the second leading cause of cancer mortality in U.S. men (1). Age, race, family history, and possibly lycopene intake are the only established risk factors for prostate cancer; of these, only lycopene intake is modifiable (2). Physical activity, because it can decrease circulating levels of sex hormones and insulin that promote the proliferation of prostate cells, has been proposed as another modifiable prostate cancer risk factor (3, 4).

Epidemiologic studies on the association between physical activity and prostate cancer are inconclusive. Four (5-8) of 18 observational studies (5-22) suggest that physical activity may reduce prostate cancer risk but the majority do not. Two studies report that the inverse association is limited to more vigorous physical activity and/or to aggressive prostate cancer. A high level of vigorous physical activity was associated with lower risk of metastatic prostate cancer in a large prospective study of U.S. men [rate ratio (RR), 0.46; 95% confidence interval (95% CI), 0.24-0.89], but no association was seen between total physical activity and all or metastatic prostate cancer (6). Similarly, a high level of vigorous physical activity was associated with lower prostate cancer risk in a Canadian case-control study (RR, 0.70; 95% CI, 0.54-0.92; ref. 8). Recreational physical activity also was inversely associated with prostate

cancer risk among men attending a screening center in Norway (RR, 0.80; 95% CI, 0.62-1.00; ref. 5) and in a cohort of middle-aged British men (RR, 0.25; 95% CI, 0.06-0.99; ref. 7).

It remains unclear whether recreational physical activity is associated with prostate cancer risk and whether the association varies by type, dose (e.g., frequency, duration, intensity) or time period in life of physical activity or the stage at prostate cancer diagnosis. Therefore, we examined the association between various measures of physical activity and prostate cancer risk among men in the American Cancer Society Cancer Prevention Study II (CPS-II) Nutrition Cohort, a large prospective study in the United States.

Methods

Study Population. Men in this analysis were drawn from the 86,404 male participants in the CPS-II Nutrition Cohort, which was established by the American Cancer Society in 1992 as a subgroup of the larger 1982 CPS-II baseline cohort (23). Most participants were ages 50 to 74 years at enrollment in 1992. At baseline, they completed a 10-page self-administered questionnaire that included questions on demographic, medical, behavioral, environmental, and dietary factors. Follow-up questionnaires were sent to cohort members in 1997 to 1998, 1999 to 2000, and 2001 to 2002 to update exposure information and to ascertain newly diagnosed cancers. Questionnaire response rates among living cohort members are at least 90%.

We excluded from the analyses men who were lost to follow-up from 1992 to 2001 (*n* = 3,431), who reported prevalent cancer (except nonmelanoma skin cancer) at baseline (*n* = 9,004), or who did not complete the section on recreational

Received 5/13/04; revised 7/7/04; accepted 7/20/04.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Alpa V. Patel, Epidemiology and Surveillance Research, American Cancer Society, National Home Office, 1599 Clifton Road Northeast, Atlanta, GA 30329-4251. Phone: 404-329-7726; Fax: 1-404-327-6450. E-mail: Alpa.Patel@cancer.org
Copyright © 2005 American Association for Cancer Research.

physical activity at baseline ($n = 1,122$). We also excluded reported cases of prostate cancer that could not be verified through medical or cancer registry records ($n = 623$), and stage I prostate cancer cases ($n = 50$). After all exclusions, the final analytic cohort consisted of 72,174 men with a mean age at study entry of 63.9 (± 6.1 SD) years.

Case Ascertainment. A total of 5,503 verified incident cases of fatal and nonfatal prostate cancer diagnosed between the date of enrollment and August 31, 2001 were included in this analysis. Of these, 5,290 cases were identified initially by self-report on a follow-up questionnaire and subsequently verified from medical records ($n = 4,361$) or linkage with state cancer registries ($n = 929$). A small number ($n = 110$) of incident prostate cancer cases also were identified during confirmation of another reported cancer diagnosis. Incident cases ($n = 103$) were identified as interval deaths through automated linkage of the entire cohort with the National Death Index (24). For these cases, prostate cancer was listed as the primary cause of death (International Classification of Diseases, Ninth Revision, codes 185.0-185.9; Tenth Revision, codes C61.0-C61.9; refs. 25, 26) during the interval between the date of enrollment and December 31, 2000. For 72 interval deaths, additional information was obtained through linkage with state cancer registries. We further classified prostate cancer cases as "nonaggressive" ($n = 4,160$) or "aggressive" ($n = 1,343$) based on information from the medical or registry records. Aggressive prostate cancers were defined as (a) cases diagnosed at stages III and IV or Gleason Score of 8 or higher or grades 3 to 4 on medical records, (b) cases verified by a state cancer registry and classified as regional or distant, or (c) prostate cancer deaths.

Physical Activity Measures. Baseline recreational physical activity information was collected using the question "During the past year, what was the average time per week you spent at the following kinds of activities: walking, jogging/running, lap swimming, tennis or racquetball, bicycling or stationary biking, aerobics/calisthenics, and dancing?" Response to each activity included "none," "1 to 3 hours per week," "4 to 6 hours per week," or ">7 hours per week." Summary metabolic equivalent (MET)-hours/wk were calculated for each participant. A MET is the ratio of metabolic rate during a specific activity to resting metabolic rate (27). Due to the older age of this population, the summary MET score for each participant was calculated by multiplying the lowest number of hours within each category times the moderate intensity MET score for each activity according to the Compendium of Physical Activities (27) to provide conservatively estimated summary measures. The MET scores for various activities were (27) 3.5 for walking, 7.0 for jogging/running, 7.0 for lap swimming, 6.0 for tennis or racquetball, 4.0 for bicycling/stationary biking, 4.5 for aerobics/calisthenics, and 3.5 for dancing.

The baseline questionnaire also asked participants to recall physical activity at age 40 using the question, "At age 40, what was the average time per week you spent at the following kinds of activities: walking, jogging/running, lap swimming, tennis or racquetball, bicycling or stationary biking, aerobics/calisthenics, and dancing?" A summary MET score at age 40 was created using the same method described above. Recreational physical activity at baseline and age 40 were categorized in MET-hours/wk as none, >0 to 7, >7 to 14, >14 to 21, >21 to 28, >28 to 35, or >35. Another measure of past physical activity was obtained from a questionnaire completed in 1982, when participants in the CPS-II Nutrition Cohort were enrolled in the large CPS-II mortality study. The 1982 questionnaire asked "How much exercise do you get (work or play): none, slight, moderate, heavy?" Physical activity in 1982 was categorized as none, slight, moderate, or heavy. Physical activity at age 40 (as recalled in 1992) and activity reported in 1982 were examined together with baseline 1992 exposure information to assess whether risk of prostate cancer was reduced among men who consistently reported being physically active.

Statistical Analysis. We used Cox proportional hazards modeling (28) to calculate hazards RR and corresponding 95% CI to examine the relationship between measures of recreational physical activity and prostate cancer. For each physical activity exposure variable, we assessed risk in two models, one adjusted only for age and race, and the other adjusted for age, race, and other potential confounding factors. All Cox models were stratified on exact year of age at enrollment and race (white, black, and other). Potential confounders included in the multivariate models were body mass index (weight in kg/height in m^2 ; <22.0, 22.0 to <25.0, 25.0 to <27.0, 27.0 to <30.0, 30.0 to <35.0, ≥ 35.0 , and missing), weight change from age 18 to 1992 (>5 lb. loss, 5 loss to 5 gain, 6-10 gain, 11-15 gain, 16-20 gain, 21-25 gain, 36-30 gain, 31-35 gain, 36-40 gain, 41-45 gain, 46-50 gain, >50 gain, and missing), personal history of diabetes (no, < 10 or ≥ 10 years since diagnosis), long-term multivitamin use (nonuser, occasional use, past regular use, recent regular use, long-term regular use, and missing), daily caloric intake (quartiles), daily calcium intake (quartiles), daily lycopene intake (quartiles), weekly servings of red meat (quartiles), and family history of prostate cancer (yes and no). Information on history of prostate-specific antigen (PSA) testing was first collected in the 1997 questionnaire and was included in multivariate models as a time dependent covariate starting in 1997. We also examined the relationship between recreational physical activity and prostate cancer separately for nonaggressive and aggressive disease.

Trend tests for baseline and age 40 physical activity models were calculated by assigning the median MET value within each category to that category. Trend tests for physical activity in 1982 were obtained by using an ordinal variable corresponding with each level of physical activity. To test whether any of the potential confounders described above modified the association between recreational physical activity and prostate cancer risk, we constructed multiplicative interaction terms with all other risk factors. Due to small numbers in some strata, categories of potential effect modifiers were sometimes collapsed. Statistical interaction was assessed in multivariate models using the likelihood ratio test and a $P < 0.05$ was considered statistically significant (29).

Results

Approximately 12% ($n = 8,881$) of men reported no recreational physical activity at baseline (Table 1). Among physically active men (defined as those reporting any recreational physical activity at baseline), the median MET expenditure was 14.0 MET-hour/wk, corresponding to ~4 hours of moderately paced walking per week. Physically active men, regardless of level of MET expenditure, engaged primarily in activities judged to be of low intensity (walking, biking, aerobics/calisthenics, or dancing) rather than moderate or high intensity (jogging/running, swimming, or tennis/racquetball). Physically active men were more likely to be lean and less likely to have gained weight since age 18 years. Physically active men also were more likely to have no history of diabetes, use multivitamins, have higher daily intake of calcium and lycopene, and eat fewer servings of red meat (Table 1). The age-adjusted percentage of men reporting PSA testing on the 1997 and/or the 1999 questionnaire was higher among active (81.3%) than inactive men (70.5%).

No association was observed between the level of recreational physical activity at baseline and the overall risk of prostate cancer in this study (Table 2). Men in the highest category of recreational physical activity (>35.0 MET-hour/wk) had 10% lower risk of prostate cancer (RR, 0.90; 95% CI, 0.78-1.04) than men who reported no physical activity at baseline (Table 2). The test for trend was not statistically significant

Table 1. Selected characteristics in relation to baseline recreational physical activity MET expenditure among 72,174 men in the CPS-II Nutrition Cohort, 1992 to 2001

| Characteristic | Recreational leisure time activity MET expenditure | | | | |
|---|--|--------------------|--------------------|--------------------|--------------------|
| | None | >0-7 | >7-21 | >21-35 | >35 |
| No. participants (%) | 8,881 (12.3) | 21,611 (29.9) | 24,962 (34.6) | 12,666 (17.6) | 4,054 (5.6) |
| Median MET-h/wk | 0 | 3.5 | 14.0 | 24.5 | 45.5 |
| Low-intensity activity hours* (%) | N/A | 97.0 | 91.5 | 89.2 | 65.9 |
| Age at baseline (mean \pm SE) | 63.5 \pm 0.07 | 63.7 \pm 0.04 | 64.1 \pm 0.04 | 64.4 \pm 0.05 | 63.9 \pm 0.09 |
| BMI (weight kg/height m ² , mean \pm SE) | 27.2 \pm 0.04 | 26.8 \pm 0.02 | 26.2 \pm 0.02 | 26.0 \pm 0.03 | 25.5 \pm 0.06 |
| Weight change (lbs., age 18 to 1992, mean \pm SE) | 37.3 \pm 0.27 | 35.2 \pm 0.17 | 30.6 \pm 0.16 | 29.0 \pm 0.23 | 23.6 \pm 0.40 |
| Personal history of diabetes (%) | 10.7 | 9.7 | 8.3 | 8.3 | 6.5 |
| Long-term multivitamin use (%) | 7.6 | 10.4 | 12.3 | 11.7 | 14.7 |
| Daily caloric intake (kcal, mean \pm SE) | 1,903.6 \pm 6.9 | 1,781.7 \pm 4.4 | 1,759.7 \pm 4.0 | 1,851.2 \pm 5.7 | 1,824.4 \pm 10.0 |
| Daily calcium intake (mg, mean \pm SE) | 819.1 \pm 4.6 | 873.3 \pm 2.9 | 914.6 \pm 2.7 | 905.5 \pm 3.9 | 970.5 \pm 6.8 |
| Daily lycopene intake (μ g, mean \pm SE) | 4,030.6 \pm 36.3 | 4,488.6 \pm 23.1 | 4,946.9 \pm 21.4 | 4,956.0 \pm 30.2 | 5,653.3 \pm 53.0 |
| Servings of red meat/wk (mean \pm SE) | 6.7 \pm 0.05 | 5.7 \pm 0.03 | 5.1 \pm 0.03 | 5.4 \pm 0.04 | 4.5 \pm 0.07 |
| Family history of prostate cancer (%) | 10.2 | 10.5 | 10.7 | 10.6 | 10.5 |

NOTE: All values (except age and median MET-hours) are standardized to the age distribution of the study population.

*% Total activity hours that are low intensity (walking, biking, dancing, or aerobics).

with (P for trend = 0.31) or without (P for trend = 0.53) inclusion of men who reported no recreational physical activity. Similarly, no association was seen between moderate/high intensity activity (jogging/running, swimming, and tennis/racquetball) physical activity and prostate cancer risk (data not shown).

Men reporting any level of recreational physical activity had lower rates of aggressive prostate cancer compared with men

who reported no physical activity (Table 3). Physical activity of ≥ 35 MET-hours/wk was associated with a 31% lower risk of aggressive prostate cancer at diagnosis (RR, 0.69; 95% CI, 0.52-0.92; P for trend = 0.06; Table 3); however, no statistically significant dose response was seen with increasing level of physical activity and the incidence of aggressive prostate cancer when the analysis was restricted to active men (P for trend = 0.57).

Table 2. RRs for recreational leisure time physical activity at various times during a man's lifetime and prostate cancer, CPS-II Nutrition Cohort, 1992 to 2001

| | No. cases/person-years | RR* (95% CI) | RR† (95% CI) |
|--------------------|------------------------|------------------|--|
| MET-h/wk in 1992‡ | | | |
| None | 624/64,652 | 1.00 (reference) | 1.00 (reference) |
| >0-7 | 1,577/163,315 | 0.98 (0.89-1.07) | 0.95 (0.87-1.05) |
| >7-14 | 1491/142,298 | 1.04 (0.95-1.14) | 1.00 (0.91-1.09) |
| >14-21 | 553/48,431 | 1.13 (1.01-1.27) | 1.07 (0.95-1.20) |
| >21-28 | 657/69,505 | 0.93 (0.83-1.03) | 0.89 (0.79-0.99) |
| >28-35 | 297/27,203 | 1.08 (0.94-1.24) | 1.02 (0.89-1.18) |
| >35 | 304/31,437 | 0.96 (0.84-1.11) | 0.90 (0.78-1.04), $P^§$ for trend = 0.31 |
| MET-h/wk at age 40 | | | |
| None | 870/90,934 | 1.00 (reference) | 1.00 (reference) |
| >0-7 | 1,418/137,082 | 1.09 (1.00-1.18) | 1.07 (0.98-1.16) |
| >7-14 | 1,059/103,255 | 1.08 (0.99-1.18) | 1.06 (0.97-1.16) |
| >14-21 | 448/45,049 | 1.04 (0.93-1.17) | 1.01 (0.90-1.14) |
| >21-28 | 762/75,869 | 1.01 (0.91-1.11) | 1.00 (0.91-1.10) |
| >28-35 | 323/29,767 | 1.12 (0.98-1.27) | 1.09 (0.96-1.24) |
| >35 | 541/57,685 | 0.99 (0.89-1.10) | 0.96 (0.86-1.07), $P^§$ for trend = 0.15 |
| Exercise in 1982¶ | | | |
| None | 97/8,383 | 1.00 (reference) | 1.00 (reference) |
| Slight | 1,261/133,563 | 0.82 (0.66-1.00) | 0.80 (0.65-0.98) |
| Moderate | 3,424/336,119 | 0.84 (0.69-1.03) | 0.81 (0.66-0.99) |
| Heavy | 678/64,956 | 0.89 (0.72-1.10) | 0.85 (0.69-1.05), $P^§$ for trend = 0.72 |

*Age- and/or race-adjusted RR and corresponding 95% CI.

†Multivariate-adjusted RR and 95% CI adjusted for: age, race, BMI in 1992, weight change from age 18 to 1992, personal history of diabetes, long-term multivitamin use, daily caloric intake in 1992, daily calcium intake in 1992, daily lycopene intake in 1992, weekly servings of red meat in 1992, family history of prostate cancer, and personal history of PSA testing.

‡MET-hours/wk based on the following activities reported at baseline in 1992: walking, jogging/running, bicycling, swimming, aerobics/calisthenics, tennis/racquetball, and dancing.

§Trend tests conducted in multivariate models.

||MET-hours/wk calculated same as above based on recall on 1992 survey of activity at age 40 [1001 men (82 cases) excluded for missing information].

¶Physical activity reported on 1982 CPS-II survey as "how much exercise do you get?": none, slight, moderate, or heavy [513 men (43 cases) excluded for missing information].

Table 3. Rate ratios for baseline recreational leisure time physical activity and risk of nonaggressive and aggressive prostate cancer, CPS-II Nutrition Cohort, 1992 to 2001

| | No. cases/person-years | RR* (95% CI) |
|--|------------------------|---|
| Nonaggressive prostate cancer [†] | | |
| MET-h/wk in 1992 [‡] | | |
| None | 440/63,885 | 1.00 (reference) |
| >0-7 | 1,205/161,811 | 1.02 (0.92-1.14) |
| >7-21 | 1,549/188,800 | 1.07 (0.96-1.20) |
| >21-35 | 728/95,816 | 0.99 (0.88-1.11) |
| >35 | 238/31,182 | 0.98 (0.84-1.16), <i>P</i> for trend = 0.57 |
| Aggressive prostate cancer [†] | | |
| MET-h/wk in 1992 [‡] | | |
| None | 184/62,782 | 1.00 (reference) |
| >0-7 | 372/157,940 | 0.79 (0.66-0.94) |
| >7-21 | 495/183,771 | 0.87 (0.73-1.04) |
| >21-35 | 226/93,473 | 0.77 (0.63-0.94) |
| >35 | 66/30,327 | 0.69 (0.52-0.92), <i>P</i> for trend = 0.06 |

*Multivariate-adjusted RR and 95% CI adjusted for age, race, BMI in 1992, weight change from age 18 to 1992, personal history of diabetes, long-term multivitamin use, daily caloric intake in 1992, daily calcium intake in 1992, daily lycopene intake in 1992, weekly servings of red meat in 1992, family history of prostate cancer, and personal history of PSA testing.

[†]Aggressive prostate cancers included cases (a) verified by medical records with stages III and IV at diagnosis, Gleason score of 8 or higher or grades 3 to 4, (b) cases verified by the state cancer registry and classified as regional or distant, and (c) prostate cancer deaths.

[‡]MET-hours/wk based on the following activities reported at baseline in 1992: walking, jogging/running, bicycling, swimming, aerobics/calisthenics, tennis/racquetball, and dancing.

We also examined the association of prostate cancer risk with physical activity at age 40 as recalled at baseline and with reported exercise levels in 1982 (Table 2). Neither physical activity at age 40 (RR, 0.96; 95% CI, 0.86-1.07 for >35 METs versus none; *P* for trend = 0.15) nor exercise reported in 1982 (RR, 0.85; 95% CI, 0.69-1.05 for heavy versus no exercise; *P* for trend = 0.72) were associated with risk of prostate cancer. Furthermore, being physically active across multiple time points was not associated with risk of total prostate cancer (data not shown). There were no statistically significant interactions between baseline recreational physical activity levels and any of the other potential risk factors included in this analysis (data not shown).

To assess whether PSA testing might confound the relationship between physical activity and prostate cancer risk, we conducted a sensitivity analysis starting follow-up in 1997 when information on PSA testing was first collected. During this follow-up period, physical activity (>35 MET-hours/wk) was not associated with risk of total prostate cancer (RR, 0.94; 95% CI, 0.76-1.17; *P* for trend = 0.32), but physical activity (>35 MET-hours/wk) was associated with risk of aggressive prostate cancer (RR, 0.51; 95% CI, 0.30-0.87; *P* for trend = 0.05; among active men, *P* for trend = 0.17).

Discussion

In this cohort of elderly U.S. men, recreational physical activity was not associated with the overall risk of prostate cancer. No association was observed between past physical activity measures (at age 40 or 10 years before baseline) and prostate cancer risk. These findings are consistent with most previous studies that have examined the relationship between physical activity and prostate cancer risk (9-22). Being physically active, however, was associated with lower rates of aggressive prostate cancer. Similar findings were reported in the only previous study that has examined this relationship in an analysis of physical activity and metastatic prostate cancer (6).

There are several biological reasons why physical activity might inhibit the development of aggressive prostate cancer. First, physical activity may inhibit prostate cancer progression. Physical activity has been consistently associated with decreased levels of circulating insulin, and previous studies

have also observed, albeit less consistently, associations between physical activity and circulating levels of insulin-like growth factor-I, insulin-like growth factor binding proteins, and testosterone (30, 31). Two recent reports from prospective studies found that high circulating levels of insulin-like growth factor-I and low levels of IGFBP-3 may be associated with aggressive prostate cancer suggesting that insulin-like growth factor-I acts as a tumor promoter (32, 33).

The observed inverse association between physical activity and aggressive prostate cancer could also be due, in part, to confounding by PSA testing. In this study population, a history of PSA testing was slightly more common among physically active than inactive men. PSA testing would, in general, increase the overall incidence of prostate cancer diagnoses but decrease the incidence of tumors we defined as "aggressive." However, our sensitivity analysis that adjusted for history of PSA testing based on follow-up from 1997 found no evidence of confounding by PSA. Finally, chance remains a possible explanation for our finding in the subgroup of men with aggressive prostate cancer.

There are many strengths that should be mentioned including the prospective design, large sample size, and ability to adjust for known or hypothesized risk factors for prostate cancer. A limitation of this study is the assessment of physical activity since summary measures are based on frequency of physical activity with a lack of information of various time periods in life and imputed intensity. The lack of individual information on intensity of these activities increases the potential for misclassification of true energy expenditure. Another limitation is the limited range of recreational physical activities commonly done by our participants. Even among men reporting high levels of recreational physical activity, most engaged primarily in walking.

In summary, our findings are consistent with most previous studies that found no significant association between recreational physical activity and total prostate cancer risk. However, our results support an earlier finding that physical activity may be inversely associated with risk of aggressive prostate cancer. The type, intensity, and frequency of physical activity needed to affect risk remain unknown. Given the large number of men who develop prostate cancer and the paucity of modifiable risk factors, the possible relationship between physical activity and aggressive prostate cancer deserves further study.

References

1. American Cancer Society. Cancer facts & figures. Atlanta, GA: American Cancer Society; 2003.
2. Gronberg H. Prostate cancer epidemiology. *Lancet* 2003;361:859–64.
3. Oliveria SA, Lee IM. Is exercise beneficial in the prevention of prostate cancer? *Sports Medicine* 1997;23:271–8.
4. Lee IM, Sesso HD, Chen J, Paffenbarger RS. Does physical activity play a role in the prevention of prostate cancer? *Epidemiologic Reviews* 2001;23:132–7.
5. Lund Nilsen TI, Johnsen R, Vatten LJ. Socio-economic and lifestyle factors associated with the risk of prostate cancer. *British Journal of Cancer* 2000;82:1358–63.
6. Giovannucci E, Leitzmann M, Spiegelman D, et al. A prospective study of physical activity and prostate cancer in male health professionals. *Cancer Research* 1998;58:5117–22.
7. Wannamethee SG, Shaper AG, Walker M. Physical activity and risk of cancer in middle-aged men. *British Journal of Cancer* 2001;85:1311–6.
8. Friedenreich CM, McGregor SE, Courneya KS, Angyalji SJ, Elliott FG. Case-control study of lifetime total physical activity and prostate cancer risk. *American Journal of Epidemiology* 2004;159:740–9.
9. Lee IM, Sesso HD, Paffenbarger RS. A prospective cohort study of physical activity and body size in relation to prostate cancer risk (United States). *Cancer Causes and Control* 2001;12:187–93.
10. Lacey JV, Deng J, Dosemeci M, et al. Prostate cancer, benign prostatic hyperplasia and physical activity in Shanghai, China. *International Journal of Epidemiology* 2001;30:341–9.
11. Cerhan JR, Torner JC, Lynch CF, et al. Association of smoking, body mass, and physical activity with risk of prostate cancer in the Iowa 65+ Rural Health Study (United States). *Cancer Causes and Control* 1997;8:229–38.
12. Severson RK, Nomura AMY, Grove JS, Stemmermann GN. A prospective analysis of physical activity and cancer. *American Journal of Epidemiology* 1989;130:522–9.
13. Lee IM, Paffenbarger RS, Hsieh C. Physical activity and risk of prostatic cancer among college alumni. *American Journal of Epidemiology* 1992;135:169–79.
14. Thune I, Lund E. Physical activity and the risk of prostate and testicular cancer: a cohort study of 53,000 Norwegian men. *Cancer Causes & Control* 1994;5:549–56.
15. Hartman TJ, Albanes D, Rautalahti M, et al. Physical activity and prostate cancer in the α -Tocopherol β -Carotene (ATBC) Cancer Prevention Study (Finland). *Cancer Causes & Control* 1998;9:11–8.
16. Clarke G, Whittemore AS. Prostate cancer risk in relation to anthropometry and physical activity: The National Health and Nutrition Examination Survey I Epidemiological Follow-up Survey. *Cancer Epidemiology, Biomarkers & Prevention* 2000;9:875–81.
17. Liu S, Lee IM, Linson P, Ajani U, Buring JE, Hennekens CH. A prospective study of physical activity and risk of prostate cancer in US physicians. *International Journal of Epidemiology* 2000;29:29–35.
18. Whittemore AS, Kolonel LN, Wu AH, et al. Prostate cancer in relation to diet, physical activity, and body size in Blacks, Whites, and Asians in the United States and Canada. *Journal of the National Cancer Institute* 1995;87:652–61.
19. West DW, Slattery ML, Robinson LM, French TK, Mahoney AW. Adult dietary intake and prostate cancer risk in Utah: a case-control study with special emphasis on aggressive tumors. *Cancer Causes & Control* 1991;2:85–94.
20. Andersson SO, Baron J, Wolk A, Lindgren C, Bergstrom R, Adami HO. Early like risk factors for prostate cancer: a population-based case-control study in Sweden. *Cancer Epidemiology Biomarkers & Prevention* 1995;4:187–92.
21. Sung JFC, Lin RS, Pu Y, Chen Y, Chang HC, Lai M. Risk factors for prostate carcinoma in Taiwan: a case-control study in a Chinese population. *Cancer* 1999;86:484–91.
22. Villeneuve PJ, Johnson KC, Kreiger N, Mao Y. The Canadian Cancer Registries Epidemiology Research Group. Risk factors for prostate cancer: results from the Canadian National Enhanced Cancer Surveillance System. *Cancer Causes & Control* 1999;10:355–67.
23. Calle EE, Rodriguez C, Jacobs EJ, et al. The American Cancer Society Cancer Prevention Study II Nutrition Cohort-rational, study design, and baseline characteristics. *Cancer* 2002;94:500–11.
24. Calle EE, Terrell DD. Utility of the National Death Index for ascertainment of mortality among Cancer Prevention Study II participants. *American Journal of Epidemiology* 1993;137:235–41.
25. WHO. International Classification of Diseases Ninth Revision. Manual of the international statistical classification of disease, injuries, and causes of death. 9th rev. ed., vol. 1. Geneva: WHO; 1977.
26. WHO. International statistical classification of diseases and related health problems tenth revision. 10th ed., vol. 1. Geneva: WHO; 1992.
27. Ainsworth BE, Haskell WL, Leon AS, et al. Compendium of physical activities: classification of energy costs of human physical activities. *Medicine and Science in Sports and Exercise* 1993;25:71–80.
28. Cox D. Regression models and life tables. *Journal of the Royal Statistical Society* 1972;34:187–220.
29. Kleinbaum G, Kupper L, Morgenstern H. *Epidemiologic research: principles and quantitative methods*. New York: Van Nostrand Reinhold Co; 1982.
30. Hackney AC. The male reproductive system and endurance exercise. *Medicine & Science in Sports & Exercise* 1996;28:180–9.
31. IARC. IARC Handbooks on Cancer Prevention: weight control and physical activity, Vol. 6. Lyon: IARC. 2002.
32. Stattin P, Bylund A, Rinaldi S, et al. Plasma insulin-like growth factor-I, insulin-like growth factor binding proteins, and prostate cancer risk: a prospective study. *Journal of the National Cancer Institute* 2000;92:1910–17.
33. Chan JM, Stampfer MJ, Ma J, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. *Journal of the National Cancer Institute* 2002;94:1099–106.

| 論文名 | Recreational physical activity and risk of prostate cancer in a large cohort of U.S. men | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---------------------------------------|---|------------------|---|------|-----|-------|---------|--------|------------------------|--------------|--------------|--------------------------|--|--|--|------|------------|------------------|------------------|------|---------------|------------------|------------------|-------|--------------|------------------|------------------|--------|------------|------------------|------------------|--------|------------|------------------|------------------|--------|------------|------------------|------------------|-----|------------|------------------|---|---------------------------------------|--|--|--|------|------------|------------------|------------------|------|---------------|------------------|------------------|-------|---------------|------------------|------------------|--------|------------|------------------|------------------|--------|------------|------------------|------------------|--------|------------|------------------|------------------|-----|------------|------------------|---|--------------------------|--|--|--|------|----------|------------------|------------------|--------|---------------|------------------|------------------|----------|---------------|------------------|------------------|-------|------------|------------------|---|
| 著者 | Patel AV, Rodriguez C, Jacobs EJ, Solomon L, Thun MJ, Calle EE | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 雑誌名 | Cancer Epidemiol Biomarkers Prev | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 巻・号・頁 | 14(1) 275-9 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 発行年 | 2005 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| PubMedリンク | http://www.ncbi.nlm.nih.gov/pubmed/15668508 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 対象の内訳 | 対象 | ヒト | 動物 | 地域 | 欧米 | 研究の種類 | 縦断研究 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 性別 | 一般健康者 | 空白 | | () | | () | コホート研究 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 年齢 | 50-74歳 (63.9歳) | | | | | 前向きコホート | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 対象数 | 10000以上 | | | | | () | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 調査の方法 | 質問紙 | () | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| アウトカム | 予防 | なし | なし | ガン予防 | なし | | () | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 維持・改善 | なし | なし | なし | なし | () | () | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 図表 | <p>Table 2. RRs for recreational leisure time physical activity at various times during a man's lifetime and prostate cancer, CPS-II Nutrition Cohort, 1992 to 2001</p> <table border="1"> <thead> <tr> <th></th> <th>No. cases/person-years</th> <th>RR* (95% CI)</th> <th>RR* (95% CI)</th> </tr> </thead> <tbody> <tr> <td colspan="4">MET-h/wk in 1992*</td> </tr> <tr> <td>None</td> <td>624/64,652</td> <td>1.00 (reference)</td> <td>1.00 (reference)</td> </tr> <tr> <td>>0-7</td> <td>1,577/163,315</td> <td>0.98 (0.89-1.07)</td> <td>0.95 (0.87-1.05)</td> </tr> <tr> <td>>7-14</td> <td>1491/142,298</td> <td>1.04 (0.95-1.14)</td> <td>1.00 (0.91-1.09)</td> </tr> <tr> <td>>14-21</td> <td>553/48,431</td> <td>1.13 (1.01-1.27)</td> <td>1.07 (0.95-1.20)</td> </tr> <tr> <td>>21-28</td> <td>657/69,505</td> <td>0.93 (0.83-1.03)</td> <td>0.89 (0.79-0.99)</td> </tr> <tr> <td>>28-35</td> <td>297/27,203</td> <td>1.08 (0.94-1.24)</td> <td>1.02 (0.89-1.18)</td> </tr> <tr> <td>>35</td> <td>304/31,437</td> <td>0.96 (0.84-1.11)</td> <td>0.90 (0.78-1.04), P[†] for trend = 0.31</td> </tr> <tr> <td colspan="4">MET-h/wk at age 40[‡]</td> </tr> <tr> <td>None</td> <td>870/90,934</td> <td>1.00 (reference)</td> <td>1.00 (reference)</td> </tr> <tr> <td>>0-7</td> <td>1,418/137,082</td> <td>1.09 (1.00-1.18)</td> <td>1.07 (0.98-1.16)</td> </tr> <tr> <td>>7-14</td> <td>1,039/103,235</td> <td>1.08 (0.99-1.18)</td> <td>1.06 (0.97-1.16)</td> </tr> <tr> <td>>14-21</td> <td>448/45,049</td> <td>1.04 (0.93-1.17)</td> <td>1.01 (0.90-1.14)</td> </tr> <tr> <td>>21-28</td> <td>762/75,869</td> <td>1.01 (0.91-1.11)</td> <td>1.00 (0.91-1.10)</td> </tr> <tr> <td>>28-35</td> <td>323/29,767</td> <td>1.12 (0.98-1.27)</td> <td>1.09 (0.96-1.24)</td> </tr> <tr> <td>>35</td> <td>541/57,683</td> <td>0.99 (0.89-1.10)</td> <td>0.96 (0.86-1.07), P[†] for trend = 0.15</td> </tr> <tr> <td colspan="4">Exercise in 1982*</td> </tr> <tr> <td>None</td> <td>97/8,383</td> <td>1.00 (reference)</td> <td>1.00 (reference)</td> </tr> <tr> <td>Slight</td> <td>1,261/133,563</td> <td>0.82 (0.66-1.00)</td> <td>0.80 (0.65-0.98)</td> </tr> <tr> <td>Moderate</td> <td>3,424/336,119</td> <td>0.84 (0.69-1.03)</td> <td>0.81 (0.66-0.99)</td> </tr> <tr> <td>Heavy</td> <td>678/64,956</td> <td>0.89 (0.72-1.10)</td> <td>0.85 (0.69-1.05), P[†] for trend = 0.72</td> </tr> </tbody> </table> <p>*Age- and/or race-adjusted RR and corresponding 95% CI. [†]Multivariate-adjusted RR and 95% CI adjusted for: age, race, BMI in 1992, weight change from age 18 to 1992, personal history of diabetes, long-term multivitamin use, daily caloric intake in 1992, daily calcium intake in 1992, daily lycopene intake in 1992, weekly servings of red meat in 1992, family history of prostate cancer, and personal history of PSA testing. [‡]MET-hours/wk based on the following activities reported at baseline in 1992: walking, jogging/running, bicycling, swimming, aerobics/calisthenics, tennis/racquetball, and dancing. [§]Trend tests conducted in multivariate models. [¶]MET-hours/wk calculated same as above based on recall on 1992 survey of activity at age 40 [1001 men (82 cases) excluded for missing information]. Physical activity reported on 1982 CPS-II survey as "how much exercise do you get?": none, slight, moderate, or heavy [513 men (43 cases) excluded for missing information].</p> | | | | | | | | No. cases/person-years | RR* (95% CI) | RR* (95% CI) | MET-h/wk in 1992* | | | | None | 624/64,652 | 1.00 (reference) | 1.00 (reference) | >0-7 | 1,577/163,315 | 0.98 (0.89-1.07) | 0.95 (0.87-1.05) | >7-14 | 1491/142,298 | 1.04 (0.95-1.14) | 1.00 (0.91-1.09) | >14-21 | 553/48,431 | 1.13 (1.01-1.27) | 1.07 (0.95-1.20) | >21-28 | 657/69,505 | 0.93 (0.83-1.03) | 0.89 (0.79-0.99) | >28-35 | 297/27,203 | 1.08 (0.94-1.24) | 1.02 (0.89-1.18) | >35 | 304/31,437 | 0.96 (0.84-1.11) | 0.90 (0.78-1.04), P [†] for trend = 0.31 | MET-h/wk at age 40[‡] | | | | None | 870/90,934 | 1.00 (reference) | 1.00 (reference) | >0-7 | 1,418/137,082 | 1.09 (1.00-1.18) | 1.07 (0.98-1.16) | >7-14 | 1,039/103,235 | 1.08 (0.99-1.18) | 1.06 (0.97-1.16) | >14-21 | 448/45,049 | 1.04 (0.93-1.17) | 1.01 (0.90-1.14) | >21-28 | 762/75,869 | 1.01 (0.91-1.11) | 1.00 (0.91-1.10) | >28-35 | 323/29,767 | 1.12 (0.98-1.27) | 1.09 (0.96-1.24) | >35 | 541/57,683 | 0.99 (0.89-1.10) | 0.96 (0.86-1.07), P [†] for trend = 0.15 | Exercise in 1982* | | | | None | 97/8,383 | 1.00 (reference) | 1.00 (reference) | Slight | 1,261/133,563 | 0.82 (0.66-1.00) | 0.80 (0.65-0.98) | Moderate | 3,424/336,119 | 0.84 (0.69-1.03) | 0.81 (0.66-0.99) | Heavy | 678/64,956 | 0.89 (0.72-1.10) | 0.85 (0.69-1.05), P [†] for trend = 0.72 |
| | No. cases/person-years | RR* (95% CI) | RR* (95% CI) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| MET-h/wk in 1992* | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| None | 624/64,652 | 1.00 (reference) | 1.00 (reference) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| >0-7 | 1,577/163,315 | 0.98 (0.89-1.07) | 0.95 (0.87-1.05) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| >7-14 | 1491/142,298 | 1.04 (0.95-1.14) | 1.00 (0.91-1.09) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| >14-21 | 553/48,431 | 1.13 (1.01-1.27) | 1.07 (0.95-1.20) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| >21-28 | 657/69,505 | 0.93 (0.83-1.03) | 0.89 (0.79-0.99) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| >28-35 | 297/27,203 | 1.08 (0.94-1.24) | 1.02 (0.89-1.18) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| >35 | 304/31,437 | 0.96 (0.84-1.11) | 0.90 (0.78-1.04), P [†] for trend = 0.31 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| MET-h/wk at age 40[‡] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| None | 870/90,934 | 1.00 (reference) | 1.00 (reference) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| >0-7 | 1,418/137,082 | 1.09 (1.00-1.18) | 1.07 (0.98-1.16) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| >7-14 | 1,039/103,235 | 1.08 (0.99-1.18) | 1.06 (0.97-1.16) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| >14-21 | 448/45,049 | 1.04 (0.93-1.17) | 1.01 (0.90-1.14) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| >21-28 | 762/75,869 | 1.01 (0.91-1.11) | 1.00 (0.91-1.10) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| >28-35 | 323/29,767 | 1.12 (0.98-1.27) | 1.09 (0.96-1.24) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| >35 | 541/57,683 | 0.99 (0.89-1.10) | 0.96 (0.86-1.07), P [†] for trend = 0.15 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Exercise in 1982* | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| None | 97/8,383 | 1.00 (reference) | 1.00 (reference) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Slight | 1,261/133,563 | 0.82 (0.66-1.00) | 0.80 (0.65-0.98) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Moderate | 3,424/336,119 | 0.84 (0.69-1.03) | 0.81 (0.66-0.99) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Heavy | 678/64,956 | 0.89 (0.72-1.10) | 0.85 (0.69-1.05), P [†] for trend = 0.72 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 図表掲載箇所 | P277, Table2 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 概要 (800字まで) | <p>本研究は、the American Cancer Society Cancer Prevention Study II Nutrition Cohortに参加している50-74歳の男性72,174名を対象に9年間の追跡調査を行い、余暇身体活動と前立腺がんの発症との関連について検討を行った。身体活動については、「過去1年間において、次のような活動を平均週何時間行っていましたか? ウォーキング、ジョギング、ランニング、水泳、テニス、ラケットボール、自転車、エアロビクス、健康体操」。回答は「全く」「週1-3時間」「週4-6時間」「週7時間以上」であった。これらをメッツ換算し、0メッツ・時/週、0-7メッツ・時/週、7-14メッツ・時/週、14-21メッツ・時/週、21-28メッツ・時/週、28-35メッツ・時/週、35メッツ・時/週以上に分類した。身体活動のそれぞれの群における前立腺がんの発症リスクは、それぞれ、1.0、0.95(0.87-1.05)、1.0(0.91-1.09)、1.07(0.95-1.2)、0.89(0.79-0.99)、1.02(0.89-1.18)、0.90(0.78-1.04)であり、余暇身体活動が21-28メッツ・時/週であった人で有意なリスク低下が示されたのみであった。一方、前立腺がんでも、高度悪性前立腺がんについて検討すると、有意なリスク低下が認められ、余暇身体活動が増加するに従って、高度悪性前立腺がんの有意な低下が認められた。</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 結論 (200字まで) | <p>余暇身体活動は、全ての前立腺がんとは関連は認められず(一部RRIに有意差は出ているが)、悪性前立腺がんとは有意な関連が認められ、余暇身体活動を増加させることで、悪性の前立腺がんを予防できる可能性が示唆された。</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| エキスパートによるコメント (200字まで) | <p>身体活動や体力などの因子ががんの発症や進行と関連しているかは、がんの様々なステージやタイプにより異なり、単純にがんの発症としてのみ検討することでは不十分であると言える。今後はアウトカムにおいてもより詳細な検討が加えられることで、がんのステージやタイプ別の処方が可能になることが期待される。</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

担当者 村上晴香

Physical Activity and Postmenopausal Breast Cancer Risk in the NIH-AARP Diet and Health Study

Tricia M. Peters,^{1,4} Arthur Schatzkin,¹ Gretchen L. Gierach,^{2,3} Steven C. Moore,¹ James V. Lacey, Jr.,² Nicholas J. Wareham,⁴ Ulf Ekelund,⁴ Albert R. Hollenbeck,⁵ and Michael F. Leitzmann¹

¹Nutritional Epidemiology Branch and ²Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics National Cancer Institute, NIH, Bethesda, Maryland; ³Cancer Prevention Fellowship Program, Office of Preventive Oncology, National Cancer Institute, NIH, Department of Health and Human Services, Bethesda, Maryland; ⁴MRC Epidemiology Unit, Institute of Metabolic Science, Cambridge, United Kingdom; and ⁵American Association of Retired Persons, Washington, District of Columbia

Abstract

Background: Although physical activity has been associated with reduced breast cancer risk, whether this association varies across breast cancer subtypes or is modified by reproductive and lifestyle factors is unclear.

Methods: We examined physical activity in relation to postmenopausal breast cancer risk in 182,862 U.S. women in the NIH-AARP Diet and Health Study. Physical activity was assessed by self-report at baseline (1995-1996), and 6,609 incident breast cancers were identified through December 31, 2003. Cox regression was used to estimate the relative risk (RR) and 95% confidence interval (95% CI) of postmenopausal breast cancer overall and by tumor characteristics. Effect modification by select reproductive and lifestyle factors was also explored.

Results: In multivariate models, the most active women experienced a 13% lower breast cancer risk versus inactive women (RR, 0.87; 95% CI, 0.81-0.95). This inverse relation was not modified by tumor

stage or histology but was suggestively stronger for estrogen receptor (ER)-negative (RR, 0.75; 95% CI, 0.54-1.04) than ER-positive (RR, 0.97; 95% CI, 0.84-1.12) breast tumors and was suggestively stronger for overweight/obese (RR, 0.86; 95% CI, 0.77-0.96) than lean (RR, 0.95; 95% CI, 0.87-1.05) women. The inverse relation with physical activity was also more pronounced among women who had never used menopausal hormone therapy and those with a positive family history of breast cancer than their respective counterparts.

Conclusions: Physical activity was associated with reduced postmenopausal breast cancer risk, particular to ER-negative tumors. These results, along with heterogeneity in the physical activity-breast cancer relation for subgroups of menopausal hormone therapy use and adiposity, indicate that physical activity likely influences breast cancer risk via both estrogenic and estrogen-independent mechanisms. (Cancer Epidemiol Biomarkers Prev 2009;18(1):289-96)

Received 8/19/08; revised 9/17/08; accepted 10/2/08.

Grant support: Intramural Research Program of the NIH, National Cancer Institute.

Note: Current address for T.M. Peters, A. Schatzkin, S.C. Moore, and M.F. Leitzmann: Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, MSC 7232, Bethesda, MD 20892. Current address for G.L. Gierach and J.V. Lacey, Jr.: Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, MSC 7232, Bethesda, MD 20892. Current address for N.J. Wareham and U. Ekelund: MRC Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, United Kingdom CB2 0QQ. Current address for A.R. Hollenbeck: American Association of Retired Persons, 601 East Street Northwest, Washington, DC 20049.

Cancer incidence data from the Atlanta metropolitan area were collected by the Georgia Center for Cancer Statistics, Department of Epidemiology, Rollins School of Public Health, Emory University. Cancer incidence data from California were collected by the California Department of Health Services, Cancer Surveillance Section. Cancer incidence data from the Detroit metropolitan area were collected by the Michigan Cancer Surveillance Program, Community Health Administration, State of Michigan. The Florida cancer incidence data used in this report were collected by the Florida Cancer Data System under contract to the Department of Health.

Requests for reprints: Tricia M. Peters, Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Department of Health and Human Services, 6120 Executive Boulevard, MSC 7232, Bethesda, MD 20892. Phone: 301-496-7031; Fax: 301-496-6829. E-mail: peterst@mail.nih.gov

Copyright © 2009 American Association for Cancer Research.
doi:10.1158/1055-9965.EPI-08-0768

Introduction

Breast cancer is the most common cancer among women in the United States, and an estimated 182,000 new cases will be diagnosed in the United States in 2008 (1). Although certain risk factors for postmenopausal breast cancer such as genetic predisposition, age, and reproductive history are nonmodifiable, several lifestyle and behavioral characteristics are also related to risk. High levels of physical activity have been consistently associated with reduced risk of postmenopausal breast cancer independent of body size. The magnitude of this inverse association ranges from 20% to 80% across studies, with most investigations estimating 20% to 40% reduced risk (2-5), and a recent review reported similar risk reductions for both moderate and vigorous (average 22% and 26% reduced risk, respectively) physical activity (5).

Despite the accumulated evidence that an active lifestyle lowers breast cancer risk, the precise mechanism by which physical activity influences tumor development